<table>
<thead>
<tr>
<th>Table Number</th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-1</td>
<td>Estimated New Cancer Cases and Deaths for 2005</td>
</tr>
<tr>
<td>I-2</td>
<td>53-Year Trends in US Cancer Death Rates</td>
</tr>
<tr>
<td>I-3</td>
<td>Summary of Changes in Cancer Incidence and Mortality 1950-2002 and 5-Year Relative Survival Rates</td>
</tr>
<tr>
<td>I-4</td>
<td>Age-Adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates, All Races</td>
</tr>
<tr>
<td>I-5</td>
<td>Age-Adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates, Whites</td>
</tr>
<tr>
<td>I-6</td>
<td>Age-Adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates, Blacks</td>
</tr>
<tr>
<td>I-7</td>
<td>SEER Incidence and US Mortality Trends by Primary Cancer Site and Sex, All Races</td>
</tr>
<tr>
<td>I-8</td>
<td>SEER Incidence and US Mortality Trends by Primary Cancer Site and Sex, Whites</td>
</tr>
<tr>
<td>I-9</td>
<td>SEER Incidence and US Mortality Trends by Primary Cancer Site and Sex, Blacks</td>
</tr>
<tr>
<td>I-10</td>
<td>Age Distribution of Incidence Cases by Site, 1998-2002</td>
</tr>
<tr>
<td>I-11</td>
<td>Median Age of Cancer Patients at Diagnosis, 1998-2002</td>
</tr>
<tr>
<td>I-12</td>
<td>Age Distribution of Deaths by Site, 1998-2002</td>
</tr>
<tr>
<td>I-13</td>
<td>Median Age of Cancer Patients at Death, 1998-2002</td>
</tr>
<tr>
<td>I-14</td>
<td>Lifetime Risk (By Site) of Being Diagnosed with Cancer - 13 SEER Areas</td>
</tr>
<tr>
<td>I-15</td>
<td>Lifetime Risk (By Site) of Dying from Cancer - Total US</td>
</tr>
<tr>
<td>I-16</td>
<td>US Death Rates Compared to SEER Death Rates by Primary Cancer Site and Race/Ethnicity</td>
</tr>
<tr>
<td>I-17</td>
<td>US Prevalence Counts by Site and Sex, January 1, 2002</td>
</tr>
<tr>
<td>I-18</td>
<td>US Prevalence Counts by Age at Prevalence, January 1, 2002</td>
</tr>
<tr>
<td>I-19</td>
<td>Top 15 Cancer Sites by Race/Ethnicity, Incidence, Both Sexes</td>
</tr>
<tr>
<td>I-20</td>
<td>Top 15 Cancer Sites by Race/Ethnicity, Incidence, Males</td>
</tr>
<tr>
<td>I-21</td>
<td>Top 15 Cancer Sites by Race/Ethnicity, Incidence, Females</td>
</tr>
<tr>
<td>I-22</td>
<td>Top 15 Cancer Sites by Race/Ethnicity, Mortality, Both Sexes</td>
</tr>
<tr>
<td>I-23</td>
<td>Top 15 Cancer Sites by Race/Ethnicity, Mortality, Males</td>
</tr>
<tr>
<td>I-24</td>
<td>Top 15 Cancer Sites by Race/Ethnicity, Mortality, Females</td>
</tr>
</tbody>
</table>
## Chapter I
### Overview

<table>
<thead>
<tr>
<th>Number</th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-1</td>
<td>Map of SEER Geographic Areas</td>
</tr>
<tr>
<td>I-3</td>
<td>US Death Rates, Heart Disease vs Neoplasms</td>
</tr>
<tr>
<td>I-4</td>
<td>Trends in SEER Incidence and US Death Rates by Primary Cancer Site</td>
</tr>
<tr>
<td>I-5</td>
<td>Trends in SEER Incidence Rates by Primary Cancer Site, Ages &lt;65 and 65+</td>
</tr>
<tr>
<td>I-6</td>
<td>Trends in US Death Rates by Primary Cancer Site, Ages &lt;65 and 65+</td>
</tr>
<tr>
<td>I-7</td>
<td>Trends in SEER Incidence Rates by Primary Cancer Site and Sex</td>
</tr>
<tr>
<td>I-8</td>
<td>Trends in US Death Rates by Primary Cancer Site and Sex</td>
</tr>
<tr>
<td>I-9</td>
<td>SEER Incidence and US Death Rates, 5 Year Relative Survival Rates by Race and Sex</td>
</tr>
<tr>
<td>I-10</td>
<td>Trends in US Death Rates by Primary Cancer Site and Race</td>
</tr>
<tr>
<td>I-11</td>
<td>5-Year Relative Survival Rates by Race</td>
</tr>
<tr>
<td>I-12</td>
<td>SEER Cancer Incidence and US Death Rates by Cancer Site and Race/Ethnicity</td>
</tr>
<tr>
<td>I-13</td>
<td>SEER Incidence, Top 3 Male Sites by Race/Ethnicity</td>
</tr>
<tr>
<td>I-14</td>
<td>SEER Incidence, Top 3 Female Sites by Race/Ethnicity</td>
</tr>
<tr>
<td>I-15</td>
<td>US Mortality, Top 3 Male Sites by Race/Ethnicity</td>
</tr>
<tr>
<td>I-16</td>
<td>US Mortality, Top 3 Female Sites by Race/Ethnicity</td>
</tr>
<tr>
<td>I-17</td>
<td>Incidence Percent Change 1992-2002, Burden vs Risk by Cancer Site</td>
</tr>
<tr>
<td>I-18</td>
<td>Mortality Percent Change 1992-2002, Burden vs Risk by Cancer Site</td>
</tr>
<tr>
<td>I-19</td>
<td>Person and Average Years of Life Lost to Cancer (2002)</td>
</tr>
<tr>
<td>I-20</td>
<td>Person and Average Years of Life Lost to Major Causes of Death (2002)</td>
</tr>
<tr>
<td>I-21</td>
<td>SEER Incidence and Delay Adjusted Incidence Rates by Sex, All Sites</td>
</tr>
<tr>
<td>I-22</td>
<td>SEER Incidence and Delay Adjusted Incidence Rates, Both Sexes, Lung and Bronchus, Colon and Rectum</td>
</tr>
<tr>
<td>I-23</td>
<td>SEER Incidence and Delay Adjusted Incidence Rates, Top 3 Male Sites</td>
</tr>
<tr>
<td>I-24</td>
<td>SEER Incidence and Delay Adjusted Incidence Rates, Top 3 Female Sites</td>
</tr>
<tr>
<td>I-25</td>
<td>Partition of SEER Incidence Trends, All Races, Both Sexes</td>
</tr>
<tr>
<td>I-26</td>
<td>Partition of SEER Incidence Trends, All Races, Males</td>
</tr>
<tr>
<td>I-27</td>
<td>Partition of SEER Incidence Trends, All Races, Females</td>
</tr>
<tr>
<td>I-28</td>
<td>Partition of US Mortality Trends, All Races, Both Sexes</td>
</tr>
<tr>
<td>I-29</td>
<td>Partition of US Mortality Trends, All Races, Males</td>
</tr>
<tr>
<td>I-30</td>
<td>Partition of US Mortality Trends, All Races, Females</td>
</tr>
</tbody>
</table>
### Table I-1

**ESTIMATED NEW CANCER CASES AND DEATHS FOR 2005**

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Estimated New Cases</th>
<th></th>
<th>Estimated Deaths</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
</tr>
<tr>
<td><strong>All Sites</strong></td>
<td>1,972,910</td>
<td>710,040</td>
<td>662,870</td>
<td>570,280</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>29,370</td>
<td>19,100</td>
<td>10,270</td>
<td>7,320</td>
</tr>
<tr>
<td>Tongue</td>
<td>7,660</td>
<td>5,050</td>
<td>2,610</td>
<td>1,730</td>
</tr>
<tr>
<td>Mouth</td>
<td>10,070</td>
<td>5,370</td>
<td>4,700</td>
<td>1,890</td>
</tr>
<tr>
<td>Pharynx</td>
<td>8,590</td>
<td>6,520</td>
<td>2,070</td>
<td>2,130</td>
</tr>
<tr>
<td>Other Oral Cavity</td>
<td>3,050</td>
<td>2,160</td>
<td>890</td>
<td>1,570</td>
</tr>
<tr>
<td>Digestive System</td>
<td>253,500</td>
<td>134,370</td>
<td>119,130</td>
<td>136,060</td>
</tr>
<tr>
<td>Esophagus</td>
<td>14,520</td>
<td>11,220</td>
<td>3,300</td>
<td>13,570</td>
</tr>
<tr>
<td>Stomach</td>
<td>21,860</td>
<td>13,510</td>
<td>8,350</td>
<td>11,550</td>
</tr>
<tr>
<td>Small Intestine</td>
<td>5,420</td>
<td>2,840</td>
<td>2,580</td>
<td>1,070</td>
</tr>
<tr>
<td>Colon</td>
<td>104,950</td>
<td>48,290</td>
<td>56,660</td>
<td>56,290</td>
</tr>
<tr>
<td>Rectum&lt;sup&gt;b&lt;/sup&gt;</td>
<td>40,340</td>
<td>23,530</td>
<td>16,810</td>
<td></td>
</tr>
<tr>
<td>Anus, Anal Canal, and Anorectum</td>
<td>3,990</td>
<td>1,750</td>
<td>2,240</td>
<td>620</td>
</tr>
<tr>
<td>Liver and Intrahepatic Bile Duct</td>
<td>17,550</td>
<td>12,130</td>
<td>5,420</td>
<td>15,420</td>
</tr>
<tr>
<td>Gallbladder and Other Biliary Pancreas</td>
<td>32,180</td>
<td>16,100</td>
<td>16,080</td>
<td>31,800</td>
</tr>
<tr>
<td>Other Digestive System</td>
<td>5,210</td>
<td>1,670</td>
<td>3,540</td>
<td>2,400</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>184,800</td>
<td>102,420</td>
<td>82,380</td>
<td>168,140</td>
</tr>
<tr>
<td>Larynx</td>
<td>9,880</td>
<td>7,920</td>
<td>1,960</td>
<td>3,770</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>172,570</td>
<td>93,010</td>
<td>79,560</td>
<td>163,510</td>
</tr>
<tr>
<td>Other Respiratory</td>
<td>2,350</td>
<td>1,810</td>
<td>540</td>
<td>540</td>
</tr>
<tr>
<td>Bones and Joints</td>
<td>2,570</td>
<td>1,480</td>
<td>1,090</td>
<td>1,210</td>
</tr>
<tr>
<td>Soft Tissue</td>
<td>9,420</td>
<td>5,530</td>
<td>3,890</td>
<td>3,490</td>
</tr>
<tr>
<td>Skin (excl. basal &amp; squamous)</td>
<td>66,000</td>
<td>37,580</td>
<td>28,420</td>
<td>10,590</td>
</tr>
<tr>
<td>Melanoma of the Skin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>59,580</td>
<td>33,580</td>
<td>26,000</td>
<td>7,770</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>6,420</td>
<td>4,000</td>
<td>2,420</td>
<td>2,820</td>
</tr>
<tr>
<td>Breast&lt;sup&gt;b&lt;/sup&gt;</td>
<td>212,930</td>
<td>91,390</td>
<td>121,540</td>
<td>212,930</td>
</tr>
<tr>
<td>Genital Organs</td>
<td>321,050</td>
<td>241,570</td>
<td>79,480</td>
<td>59,920</td>
</tr>
<tr>
<td>Cervix (uterus)</td>
<td>10,370</td>
<td>10,370</td>
<td>3,710</td>
<td></td>
</tr>
<tr>
<td>Endometrium (uterus)</td>
<td>40,880</td>
<td>40,880</td>
<td>7,310</td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td>22,220</td>
<td>22,220</td>
<td>16,210</td>
<td></td>
</tr>
<tr>
<td>Vulva</td>
<td>3,870</td>
<td>3,870</td>
<td>870</td>
<td></td>
</tr>
<tr>
<td>Vagina and other genital organs, female</td>
<td>2,140</td>
<td>2,140</td>
<td>810</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>232,090</td>
<td>232,090</td>
<td>30,350</td>
<td>30,350</td>
</tr>
<tr>
<td>Testis</td>
<td>8,010</td>
<td>8,010</td>
<td>390</td>
<td>390</td>
</tr>
<tr>
<td>Penis and other genital organs, male</td>
<td>1,470</td>
<td>1,470</td>
<td>270</td>
<td>270</td>
</tr>
<tr>
<td>Urinary System</td>
<td>101,880</td>
<td>71,090</td>
<td>30,790</td>
<td>26,590</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>63,210</td>
<td>47,010</td>
<td>16,200</td>
<td>13,180</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>36,160</td>
<td>22,490</td>
<td>13,670</td>
<td>12,660</td>
</tr>
<tr>
<td>Ureter and other urinary organs</td>
<td>2,510</td>
<td>1,590</td>
<td>920</td>
<td>750</td>
</tr>
<tr>
<td>Eye and Orbit</td>
<td>2,120</td>
<td>1,090</td>
<td>1,030</td>
<td>230</td>
</tr>
<tr>
<td>Brain and Other Nervous System</td>
<td>18,500</td>
<td>10,620</td>
<td>7,880</td>
<td>12,760</td>
</tr>
<tr>
<td>Endocrine System</td>
<td>27,650</td>
<td>7,550</td>
<td>20,100</td>
<td>2,370</td>
</tr>
<tr>
<td>Thyroid</td>
<td>25,690</td>
<td>6,500</td>
<td>19,190</td>
<td>1,490</td>
</tr>
<tr>
<td>Other Endocrine</td>
<td>1,960</td>
<td>1,050</td>
<td>910</td>
<td>880</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>63,740</td>
<td>33,050</td>
<td>30,690</td>
<td>20,610</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>56,390</td>
<td>29,070</td>
<td>27,320</td>
<td>19,200</td>
</tr>
<tr>
<td>Myeloma</td>
<td>15,980</td>
<td>8,600</td>
<td>7,380</td>
<td>11,300</td>
</tr>
<tr>
<td>Leukemia</td>
<td>34,810</td>
<td>19,640</td>
<td>15,170</td>
<td>22,570</td>
</tr>
<tr>
<td>Lymphocytic Leukemias</td>
<td>13,700</td>
<td>7,960</td>
<td>5,740</td>
<td>6,090</td>
</tr>
<tr>
<td>Myeloid Leukemias</td>
<td>16,560</td>
<td>9,170</td>
<td>7,390</td>
<td>9,850</td>
</tr>
<tr>
<td>Other leukemia</td>
<td>4,550</td>
<td>2,510</td>
<td>2,040</td>
<td>6,630</td>
</tr>
<tr>
<td>All Other Sites&lt;sup&gt;c&lt;/sup&gt;</td>
<td>28,590</td>
<td>14,660</td>
<td>13,930</td>
<td>24,250</td>
</tr>
</tbody>
</table>


Excludes basal and squamous cell skin and in situ carcinomas except urinary bladder.

Incidence projections are based on rates from the NCI SEER Program 1979-2001.

Estimated deaths for colon & rectum cancer are combined.

Breast in situ accounts for about 58,490 new cases annually, and melanoma in situ accounts for about 46,170 new cases annually.

More deaths than cases suggests lack of specificity in recording underlying causes of death on death certificate.
Table I-2

53-YEAR TRENDS IN U.S. CANCER DEATH RATES

All Races, Males and Females

All Primary Cancer Sites Combined

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>11.1</td>
<td>4.8</td>
<td>2.4</td>
<td>-2.9</td>
<td>-2.8</td>
<td>-78.1</td>
<td></td>
</tr>
<tr>
<td>5-14</td>
<td>6.7</td>
<td>4.9</td>
<td>2.6</td>
<td>-1.1</td>
<td>-2.7</td>
<td>-60.7</td>
<td></td>
</tr>
<tr>
<td>15-24</td>
<td>8.6</td>
<td>6.4</td>
<td>4.2</td>
<td>-0.8</td>
<td>-1.6</td>
<td>-50.7</td>
<td></td>
</tr>
<tr>
<td>25-34</td>
<td>20.4</td>
<td>14.8</td>
<td>9.7</td>
<td>-1.3</td>
<td>-1.4</td>
<td>-52.3</td>
<td></td>
</tr>
<tr>
<td>35-44</td>
<td>63.6</td>
<td>52.0</td>
<td>35.7</td>
<td>-0.5</td>
<td>-1.4</td>
<td>-43.9</td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>174.2</td>
<td>177.8</td>
<td>123.7</td>
<td>0.1</td>
<td>-1.5</td>
<td>-29.0</td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>391.3</td>
<td>426.8</td>
<td>352.9</td>
<td>0.3</td>
<td>-0.7</td>
<td>-9.8</td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>710.0</td>
<td>785.1</td>
<td>792.7</td>
<td>0.4</td>
<td>0.1</td>
<td>11.6</td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>1,167.2</td>
<td>1,192.7</td>
<td>1,306.1</td>
<td>0.1</td>
<td>0.4</td>
<td>11.9</td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>1,450.7</td>
<td>1,506.7</td>
<td>1,732.5</td>
<td>-0.1</td>
<td>0.7</td>
<td>19.4</td>
<td></td>
</tr>
<tr>
<td>All Ages</td>
<td>195.4</td>
<td>202.3</td>
<td>193.5</td>
<td>0.1</td>
<td>-0.1</td>
<td>-1.0</td>
<td></td>
</tr>
</tbody>
</table>

Lung and Bronchus Cancer

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5-14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>15-24</td>
<td>0.2</td>
<td>0.1</td>
<td>-</td>
<td>-2.4</td>
<td>-1.0</td>
<td>-67.4</td>
<td></td>
</tr>
<tr>
<td>25-34</td>
<td>0.8</td>
<td>0.8</td>
<td>0.4</td>
<td>0.3</td>
<td>-1.8</td>
<td>-48.8</td>
<td></td>
</tr>
<tr>
<td>35-44</td>
<td>4.6</td>
<td>10.3</td>
<td>6.0</td>
<td>3.5</td>
<td>-2.3</td>
<td>30.6</td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>20.2</td>
<td>49.9</td>
<td>30.3</td>
<td>3.6</td>
<td>-2.3</td>
<td>49.8</td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>48.9</td>
<td>126.0</td>
<td>116.2</td>
<td>3.5</td>
<td>-0.4</td>
<td>137.8</td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>59.4</td>
<td>202.2</td>
<td>275.7</td>
<td>4.4</td>
<td>1.1</td>
<td>363.9</td>
<td></td>
</tr>
<tr>
<td>75-84</td>
<td>55.4</td>
<td>206.5</td>
<td>378.0</td>
<td>5.2</td>
<td>2.2</td>
<td>582.6</td>
<td></td>
</tr>
<tr>
<td>85+</td>
<td>42.3</td>
<td>147.7</td>
<td>299.4</td>
<td>5.2</td>
<td>2.8</td>
<td>608.0</td>
<td></td>
</tr>
<tr>
<td>All Ages</td>
<td>14.9</td>
<td>44.4</td>
<td>55.1</td>
<td>4.2</td>
<td>0.7</td>
<td>268.5</td>
<td></td>
</tr>
</tbody>
</table>

Source: NCHS public use data file for the total US.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
- Rates are per 100,000 and age-adjusted to the 2000 US Std Population (18 age groups - Census P25-1130).
- Due to coding changes throughout the years, Lung and Bronchus includes trachea and pleura.
Table I-3


Males and Females, By Primary Cancer Site

Table is temporarily unavailable and will be added soon.
Table I-4

AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
By Primary Cancer Site, Sex and Time Period

All Races

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Sites</td>
<td>469.7</td>
<td>553.3</td>
<td>413.5</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx</td>
<td>10.5</td>
<td>15.5</td>
<td>6.4</td>
</tr>
<tr>
<td>Lip</td>
<td>0.9</td>
<td>1.6</td>
<td>0.4</td>
</tr>
<tr>
<td>Tongue</td>
<td>2.6</td>
<td>3.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>1.2</td>
<td>1.6</td>
<td>0.9</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0.8</td>
<td>1.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>1.6</td>
<td>1.9</td>
<td>1.4</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>0.7</td>
<td>1.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>1.3</td>
<td>2.2</td>
<td>0.5</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.3</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.8</td>
<td>1.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; Intrahep</td>
<td>6.2</td>
<td>9.3</td>
<td>3.6</td>
</tr>
<tr>
<td>Liver</td>
<td>5.4</td>
<td>8.3</td>
<td>2.9</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>0.8</td>
<td>1.0</td>
<td>0.2</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1.2</td>
<td>0.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Other biliary</td>
<td>1.6</td>
<td>1.9</td>
<td>1.3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>11.0</td>
<td>12.5</td>
<td>9.8</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp;</td>
<td>0.6</td>
<td>0.1</td>
<td>1.0</td>
</tr>
<tr>
<td>mesentery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other digestive system</td>
<td>0.5</td>
<td>0.6</td>
<td>0.5</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>65.5</td>
<td>85.4</td>
<td>51.0</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>0.7</td>
<td>0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>Larynx</td>
<td>3.6</td>
<td>6.5</td>
<td>1.4</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>61.0</td>
<td>77.8</td>
<td>48.9</td>
</tr>
<tr>
<td>Pleura</td>
<td>0.0</td>
<td>0.1</td>
<td>-</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>0.2</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>0.9</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>2.9</td>
<td>3.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam)</td>
<td>19.0</td>
<td>24.2</td>
<td>15.4</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>17.2</td>
<td>21.8</td>
<td>14.0</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>1.8</td>
<td>2.4</td>
<td>1.4</td>
</tr>
<tr>
<td>Breast</td>
<td>73.3</td>
<td>1.2</td>
<td>134.4</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>16.6</td>
<td>0.1</td>
<td>31.0</td>
</tr>
</tbody>
</table>

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). NCHS public use data file for the total US.
b SEER 9 areas.
c SEER 9 areas.
d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.
- Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-4 - continued

#### AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES

By Primary Cancer Site, Sex and Time Period

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td>27.5</td>
<td>50.7</td>
<td>9.5</td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>4.7</td>
<td>8.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>12.9</td>
<td>23.8</td>
<td>1.1</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.3</td>
<td>0.5</td>
<td>1.2</td>
</tr>
<tr>
<td>Ovary</td>
<td>7.6</td>
<td>13.9</td>
<td>5.0</td>
</tr>
<tr>
<td>Vagina</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Vulva</td>
<td>1.3</td>
<td>2.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Other female genital system</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td>79.1</td>
<td>180.2</td>
<td>-</td>
</tr>
<tr>
<td>Prostate</td>
<td>76.0</td>
<td>173.8</td>
<td>-</td>
</tr>
<tr>
<td>Testis</td>
<td>2.6</td>
<td>5.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Penis</td>
<td>0.3</td>
<td>0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Other male genital system</td>
<td>0.1</td>
<td>0.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Urinary System:</td>
<td>32.8</td>
<td>53.4</td>
<td>17.6</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>20.3</td>
<td>36.0</td>
<td>9.1</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>11.6</td>
<td>16.2</td>
<td>8.0</td>
</tr>
<tr>
<td>Ureter</td>
<td>0.5</td>
<td>0.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>0.3</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>0.8</td>
<td>0.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Brain &amp; Nervous System: (^d)</td>
<td>6.4</td>
<td>7.6</td>
<td>5.3</td>
</tr>
<tr>
<td>Brain</td>
<td>6.0</td>
<td>7.2</td>
<td>4.9</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td>8.3</td>
<td>4.8</td>
<td>11.7</td>
</tr>
<tr>
<td>Thyroid</td>
<td>7.6</td>
<td>4.0</td>
<td>11.1</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>0.8</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>21.8</td>
<td>26.3</td>
<td>18.2</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>2.7</td>
<td>3.0</td>
<td>2.4</td>
</tr>
<tr>
<td>Non-Hodgkin</td>
<td>19.1</td>
<td>23.2</td>
<td>15.8</td>
</tr>
<tr>
<td>Myeloma</td>
<td>5.5</td>
<td>6.9</td>
<td>4.5</td>
</tr>
<tr>
<td>Leukemia:</td>
<td>12.2</td>
<td>15.9</td>
<td>9.4</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>5.6</td>
<td>7.5</td>
<td>4.0</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>1.5</td>
<td>1.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>3.6</td>
<td>5.1</td>
<td>2.4</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>0.4</td>
<td>0.7</td>
<td>0.2</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>5.8</td>
<td>7.3</td>
<td>4.7</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>3.8</td>
<td>4.7</td>
<td>3.1</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>1.6</td>
<td>2.1</td>
<td>1.2</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Kaposi Sarcoma(^\ast)</td>
<td>0.9</td>
<td>1.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Mesothelioma(^\ast)</td>
<td>1.0</td>
<td>1.9</td>
<td>0.4</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>10.5</td>
<td>11.8</td>
<td>9.5</td>
</tr>
</tbody>
</table>

**Note:** Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

\(^a\) SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). NCHS public use data file for the total US.

\(^b\) SEER 9 areas.

\(^c\) Due to coding changes, Brain & Nervous System mortality are no longer shown separately. Rate not shown for mortality. Category did not exist in mortality coding until 1999.

\(^d\) Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-5
**Age-Adjusted SEER Incidence and U.S. Mortality Rates and 5-Year Relative Survival Rates**

By Primary Cancer Site, Sex and Time Period

#### Whites

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
<td>Females</td>
<td>Males</td>
</tr>
<tr>
<td>All Sites</td>
<td>479.7</td>
<td>556.4</td>
<td>429.3</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx</td>
<td>10.5</td>
<td>15.4</td>
<td>6.4</td>
</tr>
<tr>
<td>Lip</td>
<td>1.1</td>
<td>1.9</td>
<td>0.4</td>
</tr>
<tr>
<td>Tongue</td>
<td>2.7</td>
<td>3.9</td>
<td>1.7</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>1.2</td>
<td>1.7</td>
<td>1.0</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0.8</td>
<td>1.2</td>
<td>0.5</td>
</tr>
<tr>
<td>Gum &amp; other oral cavity</td>
<td>1.7</td>
<td>1.9</td>
<td>1.4</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>0.4</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Tonsil</td>
<td>1.4</td>
<td>2.2</td>
<td>0.6</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.8</td>
<td>1.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Digestive System:</td>
<td>87.7</td>
<td>107.1</td>
<td>72.6</td>
</tr>
<tr>
<td>Liver &amp; Intrahep</td>
<td>5.0</td>
<td>7.4</td>
<td>2.9</td>
</tr>
<tr>
<td>Liver</td>
<td>4.2</td>
<td>6.4</td>
<td>2.3</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>0.8</td>
<td>1.0</td>
<td>0.6</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1.2</td>
<td>0.8</td>
<td>1.5</td>
</tr>
<tr>
<td>Other biliary</td>
<td>1.5</td>
<td>1.9</td>
<td>1.3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.9</td>
<td>12.5</td>
<td>9.5</td>
</tr>
<tr>
<td>Retropertitoneum</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>0.7</td>
<td>0.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>0.5</td>
<td>0.6</td>
<td>0.4</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>66.3</td>
<td>84.2</td>
<td>53.2</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>0.7</td>
<td>0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>Larynx</td>
<td>3.6</td>
<td>6.4</td>
<td>1.4</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>61.7</td>
<td>76.7</td>
<td>51.1</td>
</tr>
<tr>
<td>Pleura</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>0.2</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>0.9</td>
<td>1.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>2.9</td>
<td>3.6</td>
<td>2.4</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam)</td>
<td>22.7</td>
<td>28.5</td>
<td>18.6</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>20.8</td>
<td>25.9</td>
<td>17.2</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>1.9</td>
<td>2.6</td>
<td>1.5</td>
</tr>
<tr>
<td>Breast</td>
<td>76.3</td>
<td>1.2</td>
<td>141.1</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>16.9</td>
<td>0.2</td>
<td>31.9</td>
</tr>
</tbody>
</table>

**Note:** Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 9 areas.

<sup>d</sup> Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-5 - continued

#### Age-adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates

By Primary Cancer Site, Sex and Time Period

**Whites**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>28.5</td>
<td>53.1</td>
<td>9.3</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>13.6</td>
<td>25.3</td>
<td>4.1</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.2</td>
<td>0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>Ovary</td>
<td>8.0</td>
<td>14.8</td>
<td>5.2</td>
</tr>
<tr>
<td>Vagina</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Vulva</td>
<td>1.4</td>
<td>2.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Other female</td>
<td>0.4</td>
<td>0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Female genital system</td>
<td>78.2</td>
<td>176.4</td>
<td>9.0</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>3.2</td>
<td>6.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Penis</td>
<td>0.3</td>
<td>0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Other male</td>
<td>0.1</td>
<td>0.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>22.5</td>
<td>39.7</td>
<td>9.9</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>12.0</td>
<td>16.7</td>
<td>8.3</td>
</tr>
<tr>
<td>Ureter</td>
<td>0.5</td>
<td>0.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>0.3</td>
<td>0.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>0.9</td>
<td>1.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>7.1</td>
<td>8.4</td>
<td>6.0</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td>6.7</td>
<td>8.1</td>
<td>5.6</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>8.6</td>
<td>5.0</td>
<td>12.2</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>7.9</td>
<td>4.2</td>
<td>11.7</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>23.1</td>
<td>27.6</td>
<td>19.4</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>2.9</td>
<td>3.3</td>
<td>2.6</td>
</tr>
<tr>
<td>Non-Hodgkin</td>
<td>20.2</td>
<td>24.4</td>
<td>16.7</td>
</tr>
<tr>
<td>Myeloma</td>
<td>5.2</td>
<td>6.7</td>
<td>4.1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>12.9</td>
<td>16.9</td>
<td>9.9</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>6.1</td>
<td>8.2</td>
<td>4.4</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>1.7</td>
<td>1.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>3.9</td>
<td>5.6</td>
<td>2.6</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>0.5</td>
<td>0.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic</td>
<td>6.0</td>
<td>7.6</td>
<td>4.9</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>3.9</td>
<td>4.9</td>
<td>3.3</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>1.6</td>
<td>2.1</td>
<td>1.3</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Other</td>
<td>0.8</td>
<td>1.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Other acute</td>
<td>0.4</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Ateukemic, subleuk &amp; NOS</td>
<td>0.4</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Kaposis Sarcoma*</td>
<td>0.8</td>
<td>1.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Mesothelioma*</td>
<td>1.1</td>
<td>2.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>10.5</td>
<td>11.8</td>
<td>9.5</td>
</tr>
</tbody>
</table>

**Note:** Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

*SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

bNCHS public use data file for the total US.
cSEER 9 areas.
dDue to coding changes, Brain & Nervous System mortality are no longer shown separately.
Rate not shown for mortality. Category did not exist in mortality coding until 1999.
Statistic could not be calculated due to less than 25 cases in the time interval.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total - Males - Females</td>
<td>Total - Males - Females</td>
<td>Total - Males - Females</td>
</tr>
<tr>
<td>All Sites</td>
<td>512.3 682.6 398.5</td>
<td>248.1 339.4 194.3</td>
<td>56.0 58.4 53.2</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>11.6 19.0 6.1</td>
<td>4.1 7.1 1.9</td>
<td>39.5 34.3 52.0</td>
</tr>
<tr>
<td>Lip</td>
<td>0.2 - -</td>
<td>- - -</td>
<td>- - -</td>
</tr>
<tr>
<td>Tongue</td>
<td>2.7 4.3 1.4</td>
<td>0.8 1.4 0.4</td>
<td>37.0 34.7 42.6</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.9 1.1 0.8</td>
<td>0.2 0.2 0.2</td>
<td>74.9 64.9 85.4</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>1.1 1.9 0.4</td>
<td>0.1 0.2 0.0</td>
<td>40.0 29.3 62.4</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>1.9 2.8 1.3</td>
<td>0.6 0.9 0.3</td>
<td>46.4 36.2 64.8</td>
</tr>
<tr>
<td>oral cavity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>0.6 0.9 0.4</td>
<td>0.3 0.5 0.2</td>
<td>41.0 47.1 20.6</td>
</tr>
<tr>
<td>Tonsil</td>
<td>1.8 3.3 0.7</td>
<td>0.4 0.7 0.1</td>
<td>35.2 31.8 47.7</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.6 1.1 -</td>
<td>0.4 0.8 0.2</td>
<td>30.4 32.9 -</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>1.4 2.6 0.4</td>
<td>0.2 0.4 0.1</td>
<td>16.0 17.3 11.5</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>0.4 0.8 -</td>
<td>1.1 2.1 0.4</td>
<td>18.2 17.8 -</td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>112.8 138.2 95.1</td>
<td>66.1 86.1 52.6</td>
<td>36.5 33.8 39.2</td>
</tr>
<tr>
<td>Liver</td>
<td>6.5 10.4 3.6</td>
<td>6.5 11.2 3.2</td>
<td>9.6 8.6 11.6</td>
</tr>
<tr>
<td>Stomach</td>
<td>12.9 17.7 9.6</td>
<td>8.8 12.8 6.3</td>
<td>22.8 21.5 24.2</td>
</tr>
<tr>
<td>Small intestine</td>
<td>3.2 4.0 2.7</td>
<td>0.6 0.7 0.5</td>
<td>48.1 44.6 50.9</td>
</tr>
<tr>
<td>Colon &amp; Rectum:</td>
<td>62.4 72.5 56.0</td>
<td>27.9 34.0 24.1</td>
<td>55.0 55.9 54.3</td>
</tr>
<tr>
<td>Colon</td>
<td>48.4 55.0 44.4</td>
<td>- - -</td>
<td>54.7 56.3 53.6</td>
</tr>
<tr>
<td>Rectum</td>
<td>14.0 17.4 11.6</td>
<td>- - -</td>
<td>56.0 55.0 57.0</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>1.6 1.8 1.4</td>
<td>0.2 0.2 0.2</td>
<td>57.1 51.8 61.9</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>86.0 126.7 58.2</td>
<td>67.0 107.0 41.0</td>
<td>16.6 16.0 17.7</td>
</tr>
<tr>
<td>Larynx</td>
<td>6.2 11.5 2.3</td>
<td>2.6 5.2 0.9</td>
<td>51.2 53.3 45.2</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>78.8 113.9 55.2</td>
<td>64.1 101.3 39.9</td>
<td>13.2 11.6 15.6</td>
</tr>
<tr>
<td>Pleura d</td>
<td>- - -</td>
<td>0.1 0.1 0.1</td>
<td>- - -</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>0.2 - -</td>
<td>0.1 0.2 0.1</td>
<td>22.0 17.4 -</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>0.7 0.8 0.6</td>
<td>0.4 0.6 0.3</td>
<td>69.7 70.0 68.4</td>
</tr>
<tr>
<td>Soft tissue incl heart</td>
<td>3.0 3.5 2.6</td>
<td>1.5 1.6 1.5</td>
<td>60.8 58.7 63.0</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squa)</td>
<td>2.2 2.6 1.9</td>
<td>1.1 1.6 0.7</td>
<td>88.6 85.8 88.8</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>1.0 1.3 0.8</td>
<td>0.4 0.5 0.4</td>
<td>77.5 75.7 78.2</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>1.2 1.3 1.1</td>
<td>0.6 1.1 0.3</td>
<td>96.1 93.5 95.6</td>
</tr>
<tr>
<td>Breast</td>
<td>68.9 1.9 119.4</td>
<td>20.6 0.6 34.7</td>
<td>75.7 56.0 75.9</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>15.5 - 27.3 -</td>
<td>- - -</td>
<td>100.0 - 100.0</td>
</tr>
</tbody>
</table>

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

SEER public use data file for the total US.

SEER 9 areas.

Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-6 - continued

**AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES**

**By Primary Cancer Site, Sex and Time Period**

**Blacks**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>25.1</td>
<td>43.6</td>
<td>12.4</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>10.5</td>
<td>18.2</td>
<td>1.9</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.5</td>
<td>0.8</td>
<td>2.4</td>
</tr>
<tr>
<td>Ovary</td>
<td>5.8</td>
<td>9.9</td>
<td>4.4</td>
</tr>
<tr>
<td>Vagina</td>
<td>0.6</td>
<td>1.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Vulva</td>
<td>1.0</td>
<td>1.7</td>
<td>0.2</td>
</tr>
<tr>
<td>Other female</td>
<td>0.4</td>
<td>0.7</td>
<td>0.2</td>
</tr>
<tr>
<td>genitourinary system</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Male Genital System:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>21.6</td>
<td>20.1</td>
<td>7.7</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>13.7</td>
<td>19.4</td>
<td>9.7</td>
</tr>
<tr>
<td>Ureter</td>
<td>0.3</td>
<td>0.4</td>
<td>0.0</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>1.0</td>
<td>0.7</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>0.2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Brain & Nervous System:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Brain &amp; Nervous system</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>3.5</td>
<td>4.2</td>
<td>3.0</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td>0.4</td>
<td>0.4</td>
<td>0.5</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.4</td>
<td>2.2</td>
<td>6.2</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>0.7</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Lymphoma:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>2.5</td>
<td>3.0</td>
<td>2.0</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>14.2</td>
<td>17.6</td>
<td>11.6</td>
</tr>
</tbody>
</table>

### Myeloma:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Leukemia:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>9.7</td>
<td>12.4</td>
<td>7.8</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>3.8</td>
<td>5.1</td>
<td>2.9</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>0.8</td>
<td>0.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>2.8</td>
<td>3.9</td>
<td>2.0</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>5.1</td>
<td>6.3</td>
<td>4.2</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>3.3</td>
<td>4.1</td>
<td>2.8</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>1.4</td>
<td>1.9</td>
<td>1.0</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td>0.7</td>
<td>0.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Other acute</td>
<td>0.4</td>
<td>0.5</td>
<td>0.7</td>
</tr>
<tr>
<td>Atelectasis, subpleural &amp; NOS</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Kaposi Sarcoma&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.8</td>
<td>3.7</td>
<td>-</td>
</tr>
<tr>
<td>Mesothelioma&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.6</td>
<td>1.1</td>
<td>-</td>
</tr>
</tbody>
</table>

### Ill-defined & unspecified:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Myeloma</td>
<td>11.0</td>
<td>13.1</td>
<td>9.5</td>
</tr>
</tbody>
</table>

**Note:** Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 9 areas.

<sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately. Rate not shown for mortality. Category did not exist in mortality coding until 1999.

<sup>e</sup> Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-7
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
All Races, 1992-2002

<table>
<thead>
<tr>
<th>Site</th>
<th>Total</th>
<th>US Mortalityb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>APC</td>
<td>Males</td>
</tr>
<tr>
<td>All Sites</td>
<td>-0.6c</td>
<td>-1.3c</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>-1.5c</td>
<td>-1.8c</td>
</tr>
<tr>
<td>Lip</td>
<td>-4.7c</td>
<td>-5.9c</td>
</tr>
<tr>
<td>Tongue</td>
<td>0.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>-4.4c</td>
<td>-4.4c</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>-2.4c</td>
<td>-2.7c</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>-1.4c</td>
<td>-2.0c</td>
</tr>
<tr>
<td>Tonsil</td>
<td>1.3c</td>
<td>2.3c</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>-1.8c</td>
<td>-2.7</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>-3.6c</td>
<td>-3.9c</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>-5.6c</td>
<td>-6.2c</td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>0.0</td>
<td>0.3</td>
</tr>
<tr>
<td>Stomach</td>
<td>-1.5c</td>
<td>-2.1c</td>
</tr>
<tr>
<td>Small intestine</td>
<td>1.9c</td>
<td>1.5</td>
</tr>
<tr>
<td>Colon &amp; Rectum:</td>
<td>-0.8c</td>
<td>-1.2c</td>
</tr>
<tr>
<td>Colon</td>
<td>-0.9c</td>
<td>-1.3c</td>
</tr>
<tr>
<td>Rectum</td>
<td>-0.6</td>
<td>-0.9c</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>1.9c</td>
<td>1.9</td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>3.3c</td>
<td>3.0c</td>
</tr>
<tr>
<td>Liver</td>
<td>4.2c</td>
<td>3.7c</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>-1.3</td>
<td>-1.7</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>-1.7c</td>
<td>-1.3c</td>
</tr>
<tr>
<td>Other biliary</td>
<td>0.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>-0.3</td>
<td>-0.4c</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>-0.6</td>
<td>0.9</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>9.2c</td>
<td>-1.6c</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>5.0c</td>
<td>3.2c</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>-1.3</td>
<td>-1.8</td>
</tr>
<tr>
<td>Larynx</td>
<td>-3.0c</td>
<td>-3.3c</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>-1.3c</td>
<td>-2.2c</td>
</tr>
<tr>
<td>Pleura</td>
<td>2.1</td>
<td>1.5</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>-3.6c</td>
<td>-4.0c</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>-0.6</td>
<td>-0.7</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>1.2c</td>
<td>1.8c</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squamous):</td>
<td>2.3c</td>
<td>2.4c</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>2.4c</td>
<td>2.5c</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>1.3</td>
<td>1.5</td>
</tr>
<tr>
<td>Breast</td>
<td>0.2</td>
<td>1.0</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>5.2c</td>
<td>4.2</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.
SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- The APC is significantly different from zero (p<.05).
- Statistic could not be calculated.
### Table I-7 - continued

#### SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX

All Races, 1992-2002

<table>
<thead>
<tr>
<th>Site</th>
<th>Incidence$^a$</th>
<th>US Mortality$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total APC</td>
<td>Males APC</td>
</tr>
<tr>
<td></td>
<td>Males APC</td>
<td>Females APC</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>-1.0$^c$</td>
<td>-0.8$^c$</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>-2.9$^c$</td>
<td>-2.8$^c$</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>-0.4</td>
<td>-0.2</td>
</tr>
<tr>
<td>Ovary</td>
<td>-1.1$^c$</td>
<td>-0.8$^c$</td>
</tr>
<tr>
<td>Vagina</td>
<td>-1.3</td>
<td>-1.0</td>
</tr>
<tr>
<td>Vulva</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Other female</td>
<td>0.5</td>
<td>0.6</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td>-1.3</td>
<td>-1.9$^c$</td>
</tr>
<tr>
<td>Prostate</td>
<td>-1.3</td>
<td>-2.0$^c$</td>
</tr>
<tr>
<td>Testis</td>
<td>1.1$^c$</td>
<td>1.1$^c$</td>
</tr>
<tr>
<td>Penis</td>
<td>-1.0</td>
<td>-1.4</td>
</tr>
<tr>
<td>Other male</td>
<td>0.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0.4$^c$</td>
<td>0.2</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>-0.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Ureter</td>
<td>1.5$^c$</td>
<td>1.4$^c$</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>-0.9</td>
<td>-1.3</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>-2.0</td>
<td>-1.7</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:</td>
<td>-1.1</td>
<td>-1.6</td>
</tr>
<tr>
<td>Brain</td>
<td>-0.6$^c$</td>
<td>-0.7</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td>-0.5$^c$</td>
<td>-0.6</td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.0$^c$</td>
<td>2.7$^c$</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>4.3$^c$</td>
<td>3.1$^c$</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Lymphoma:</td>
<td>0.0</td>
<td>-0.4</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>-0.3</td>
<td>-0.1</td>
</tr>
<tr>
<td>Myeloma</td>
<td>-0.5</td>
<td>-0.5</td>
</tr>
<tr>
<td>Leukemia:</td>
<td>-0.9$^c$</td>
<td>-1.1$^c$</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>-1.5$^c$</td>
<td>-1.4$^c$</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>0.7</td>
<td>-0.1</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>-2.3$^c$</td>
<td>-2.1$^c$</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>-1.5$^c$</td>
<td>-2.4$^c$</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>1.2$^c$</td>
<td>1.3$^c$</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>3.0$^c$</td>
<td>4.4$^c$</td>
</tr>
<tr>
<td>Other:</td>
<td>-1.1</td>
<td>-2.0</td>
</tr>
<tr>
<td>Kaposi Sarcoma$^a$</td>
<td>-20.0$^c$</td>
<td>-20.4$^c$</td>
</tr>
<tr>
<td>Mesothelioma$^a$</td>
<td>-1.1$^c$</td>
<td>-1.5$^c$</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>-3.3$^c$</td>
<td>-3.7$^c$</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

NCI public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

The APC is significantly different from zero (p<.05).

Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

Category did not exist in mortality coding until 1999.

Statistic could not be calculated.
<table>
<thead>
<tr>
<th>Site</th>
<th>Incidence $^a$</th>
<th>US Mortality $^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total APC</td>
<td>Males APC</td>
</tr>
<tr>
<td>All Sites</td>
<td>-0.4$^c$</td>
<td>-1.3$^c$</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>-1.2$^c$</td>
<td>-1.5$^c$</td>
</tr>
<tr>
<td>Lip</td>
<td>-4.5$^c$</td>
<td>-5.7$^c$</td>
</tr>
<tr>
<td>Tongue</td>
<td>0.9$^c$</td>
<td>1.0$^c$</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.6</td>
<td>0.5</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>-4.1$^c$</td>
<td>-4.0$^c$</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>-2.3$^c$</td>
<td>-2.6$^c$</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>-1.8$^c$</td>
<td>-2.1$^c$</td>
</tr>
<tr>
<td>Tonsil</td>
<td>2.0$^c$</td>
<td>2.9$^c$</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>-1.5</td>
<td>-2.4</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>-3.1$^c$</td>
<td>-3.6$^c$</td>
</tr>
<tr>
<td>Other oral cavity</td>
<td>-5.4$^c$</td>
<td>-6.4$^c$</td>
</tr>
<tr>
<td>Digestive System:</td>
<td>-0.3</td>
<td>-0.6$^c$</td>
</tr>
<tr>
<td>Esophagus</td>
<td>1.2$^c$</td>
<td>1.5$^c$</td>
</tr>
<tr>
<td>Stomach</td>
<td>-1.6</td>
<td>-2.1$^c$</td>
</tr>
<tr>
<td>Small intestine</td>
<td>1.7$^c$</td>
<td>1.3$^c$</td>
</tr>
<tr>
<td>Colon &amp; Rectum:</td>
<td>-0.9$^c$</td>
<td>-1.3$^c$</td>
</tr>
<tr>
<td>Colon</td>
<td>-1.0</td>
<td>-1.4$^c$</td>
</tr>
<tr>
<td>Rectum</td>
<td>-0.7</td>
<td>-1.0$^c$</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>2.4$^c$</td>
<td>2.4$^c$</td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>3.5$^c$</td>
<td>2.9$^c$</td>
</tr>
<tr>
<td>Liver</td>
<td>4.6$^c$</td>
<td>3.8$^c$</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>-1.4</td>
<td>-3.1</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>-1.5$^c$</td>
<td>-0.6$^c$</td>
</tr>
<tr>
<td>Other biliary</td>
<td>0.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>0.0</td>
<td>2.1$^c$</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>9.4$^c$</td>
<td>-1.6</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>4.8$^c$</td>
<td>3.0</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>-1.2</td>
<td>-2.2$^c$</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>-1.0</td>
<td>-1.5</td>
</tr>
<tr>
<td>Larynx</td>
<td>-2.9$^c$</td>
<td>-3.3$^c$</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>-1.1$^c$</td>
<td>-2.1$^c$</td>
</tr>
<tr>
<td>Pleura</td>
<td>1.8</td>
<td>2.8$^c$</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>-2.9$^c$</td>
<td>-3.2$^c$</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>-0.4</td>
<td>-0.8</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>1.4$^c$</td>
<td>1.7$^c$</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squamous)</td>
<td>2.8$^c$</td>
<td>2.8$^c$</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>2.9$^c$</td>
<td>2.9$^c$</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>1.6$^c$</td>
<td>1.7$^c$</td>
</tr>
<tr>
<td>Breast</td>
<td>0.3</td>
<td>1.4</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>5.1$^c$</td>
<td>5.8$^c$</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

The APC is significantly different from zero (p<.05).

Statistic could not be calculated.
<table>
<thead>
<tr>
<th>Site</th>
<th>Incidencea</th>
<th>US Mortalityb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>-0.9c</td>
<td>-0.9c</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>-2.4c</td>
<td>-2.9c</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>-0.6c</td>
<td>-1.7c</td>
</tr>
<tr>
<td>Ovary</td>
<td>-1.0c</td>
<td>-0.6c</td>
</tr>
<tr>
<td>Vagina</td>
<td>-0.6</td>
<td>-1.9c</td>
</tr>
<tr>
<td>Vulva</td>
<td>0.7</td>
<td>-0.3</td>
</tr>
<tr>
<td>Other female</td>
<td>0.6</td>
<td>4.2c</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td>-1.3</td>
<td>-3.2c</td>
</tr>
<tr>
<td>Prostate</td>
<td>-1.4</td>
<td>-3.3c</td>
</tr>
<tr>
<td>Testis</td>
<td>1.3c</td>
<td>-0.5</td>
</tr>
<tr>
<td>Penis</td>
<td>-0.7</td>
<td>-0.6</td>
</tr>
<tr>
<td>Other male</td>
<td>0.6</td>
<td>1.7</td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0.5c</td>
<td>0.3</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>1.7c</td>
<td>1.5c</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>-1.3</td>
<td>-1.8c</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>-0.7</td>
<td>-3.3c</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:</td>
<td>-0.3</td>
<td>-0.8c</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.4c</td>
<td>3.1c</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>1.5c</td>
<td>1.4</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>0.0</td>
<td>-0.4</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>-0.3</td>
<td>-0.4</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0.1</td>
<td>-0.4</td>
</tr>
<tr>
<td>Leukemia:</td>
<td>-0.4</td>
<td>-0.3</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>-0.8c</td>
<td>-1.1c</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>1.0c</td>
<td>2.5c</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>-2.2c</td>
<td>-2.8c</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>-1.3</td>
<td>-3.8c</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic</td>
<td>0.1c</td>
<td>0.5c</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>1.3c</td>
<td>1.2c</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>-2.1c</td>
<td>-5.8c</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>3.7c</td>
<td>2.4</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>-1.2</td>
<td>8.6c</td>
</tr>
<tr>
<td>Other:</td>
<td>-3.6c</td>
<td>-1.7</td>
</tr>
<tr>
<td>Other acute</td>
<td>-6.1c</td>
<td>-3.9c</td>
</tr>
<tr>
<td>Kaposi Sarcoma*</td>
<td>-22.0c</td>
<td>-6.9c</td>
</tr>
<tr>
<td>Mesothelioma*</td>
<td>-0.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecifed</td>
<td>-3.0c</td>
<td>0.6</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

The APC is significantly different from zero (p<.05).

Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

* Statistic could not be calculated.
Table I-9
SEER incidence and U.S. mortality trends by primary cancer site and sex
Blacks, 1992-2002

<table>
<thead>
<tr>
<th>Site</th>
<th>Total APC</th>
<th>Males APC</th>
<th>Females APC</th>
<th>Total US</th>
<th>Males US</th>
<th>Females US</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>-1.0c</td>
<td>-1.7c</td>
<td>-0.2c</td>
<td>-1.5c</td>
<td>-2.0c</td>
<td>-0.8c</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx</td>
<td>-2.8c</td>
<td>-3.1c</td>
<td>-1.7c</td>
<td>-4.3c</td>
<td>-4.6c</td>
<td>-3.5c</td>
</tr>
<tr>
<td>Lip</td>
<td>-1.2c</td>
<td>-</td>
<td>-</td>
<td>-2.0c</td>
<td>-2.3c</td>
<td>-0.5c</td>
</tr>
<tr>
<td>Tongue</td>
<td>-1.5c</td>
<td>-3.0c</td>
<td>1.7c</td>
<td>-5.9c</td>
<td>-5.9c</td>
<td>-5.9c</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>-1.4c</td>
<td>-1.8c</td>
<td>-0.6c</td>
<td>-1.4c</td>
<td>-3.6c</td>
<td>1.8c</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>-5.7c</td>
<td>-5.6c</td>
<td>-5.0c</td>
<td>-9.9c</td>
<td>-9.9c</td>
<td>-8.9c</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>-3.0c</td>
<td>-3.5c</td>
<td>-1.6c</td>
<td>-6.1c</td>
<td>-6.1c</td>
<td>-5.8c</td>
</tr>
<tr>
<td>oral cavity</td>
<td>-2.1c</td>
<td>-2.7c</td>
<td>-0.7c</td>
<td>-1.1c</td>
<td>-3.1c</td>
<td>3.2c</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>-1.5c</td>
<td>-0.7c</td>
<td>-3.7c</td>
<td>-4.5c</td>
<td>-4.5c</td>
<td>-4.3c</td>
</tr>
<tr>
<td>Tonsil</td>
<td>-2.1c</td>
<td>-3.1c</td>
<td>4.3c</td>
<td>-1.8c</td>
<td>-1.8c</td>
<td>2.0c</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>-5.0c</td>
<td>-4.4c</td>
<td>-6.2c</td>
<td>-6.8c</td>
<td>-7.5c</td>
<td>-4.1c</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>-5.3c</td>
<td>-2.9c</td>
<td>-</td>
<td>-3.1c</td>
<td>-3.1c</td>
<td>-3.1c</td>
</tr>
<tr>
<td>Other oral cavity</td>
<td>-0.6c</td>
<td>-1.0c</td>
<td>-0.2c</td>
<td>-1.3c</td>
<td>-1.5c</td>
<td>-1.0c</td>
</tr>
<tr>
<td>&amp; pharynx</td>
<td>-5.1c</td>
<td>-5.7c</td>
<td>-4.0c</td>
<td>-4.1c</td>
<td>-4.4c</td>
<td>-3.3c</td>
</tr>
<tr>
<td>Digestive System:</td>
<td>-1.5c</td>
<td>-2.8c</td>
<td>0.0c</td>
<td>-2.6c</td>
<td>-3.0c</td>
<td>-2.1c</td>
</tr>
<tr>
<td>Esophagus</td>
<td>3.9c</td>
<td>3.7c</td>
<td>4.6c</td>
<td>-0.5c</td>
<td>-0.1c</td>
<td>-0.8c</td>
</tr>
<tr>
<td>Colon &amp; Rectum</td>
<td>-0.3c</td>
<td>-0.5c</td>
<td>-0.1c</td>
<td>-0.8c</td>
<td>-0.8c</td>
<td>-0.9c</td>
</tr>
<tr>
<td>Colon</td>
<td>-0.3c</td>
<td>-0.4c</td>
<td>-0.2c</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rectum</td>
<td>-0.4c</td>
<td>-1.0c</td>
<td>0.4c</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>2.3c</td>
<td>2.3c</td>
<td>2.5c</td>
<td>-1.8c</td>
<td>-1.5c</td>
<td>-2.6c</td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>3.5c</td>
<td>4.5c</td>
<td>1.4c</td>
<td>1.3c</td>
<td>1.3c</td>
<td>0.7c</td>
</tr>
<tr>
<td>Liver</td>
<td>3.7c</td>
<td>4.8c</td>
<td>1.4c</td>
<td>0.7c</td>
<td>1.0c</td>
<td>-0.3c</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>1.4c</td>
<td>1.3c</td>
<td>1.7c</td>
<td>4.8c</td>
<td>4.0c</td>
<td>5.5c</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>-0.3c</td>
<td>-3.9c</td>
<td>8.2c</td>
<td>-0.2c</td>
<td>-0.7c</td>
<td>-0.2c</td>
</tr>
<tr>
<td>Other biliary</td>
<td>0.6c</td>
<td>1.0c</td>
<td>0.0c</td>
<td>-1.9c</td>
<td>0.3c</td>
<td>-2.9c</td>
</tr>
<tr>
<td>Pancreas</td>
<td>-1.9c</td>
<td>-2.5c</td>
<td>-1.6c</td>
<td>-1.1c</td>
<td>-1.5c</td>
<td>-0.8c</td>
</tr>
<tr>
<td>Retropertitoneum</td>
<td>-2.1c</td>
<td>-1.9c</td>
<td>-1.3c</td>
<td>-6.4c</td>
<td>-2.3c</td>
<td>-9.3c</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentry</td>
<td>6.7c</td>
<td>-</td>
<td>8.4c</td>
<td>5.3c</td>
<td>-0.8c</td>
<td>6.0c</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>-1.5c</td>
<td>-2.5c</td>
<td>0.3c</td>
<td>-1.6c</td>
<td>-2.5c</td>
<td>0.3c</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>-3.1c</td>
<td>-1.6c</td>
<td>-4.4c</td>
<td>-6.5c</td>
<td>-7.3c</td>
<td>-6.4c</td>
</tr>
<tr>
<td>Larynx</td>
<td>-3.2c</td>
<td>-3.2c</td>
<td>-3.0c</td>
<td>-2.8c</td>
<td>-2.9c</td>
<td>-2.3c</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>-1.4c</td>
<td>-2.5c</td>
<td>0.5c</td>
<td>-1.5c</td>
<td>-2.5c</td>
<td>0.4c</td>
</tr>
<tr>
<td>Pleura</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-7.6c</td>
<td>-8.8c</td>
<td>-4.6c</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>-0.5c</td>
<td>-</td>
<td>-</td>
<td>-7.2c</td>
<td>-4.7c</td>
<td>-10.5c</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>-1.5c</td>
<td>-0.9c</td>
<td>-3.1c</td>
<td>-3.1c</td>
<td>-3.7c</td>
<td>-3.2c</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>1.0c</td>
<td>2.5c</td>
<td>-0.2c</td>
<td>-3.1c</td>
<td>-0.3c</td>
<td>-4.9c</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam):</td>
<td>0.5c</td>
<td>1.5c</td>
<td>-0.7c</td>
<td>-3.8c</td>
<td>-3.5c</td>
<td>-4.0c</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>-0.7c</td>
<td>0.3c</td>
<td>-1.4c</td>
<td>-1.5c</td>
<td>-0.5c</td>
<td>-2.0c</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>1.2c</td>
<td>2.2c</td>
<td>0.1c</td>
<td>-5.2c</td>
<td>-4.6c</td>
<td>-6.6c</td>
</tr>
<tr>
<td>Breast</td>
<td>-0.2c</td>
<td>4.0c</td>
<td>-0.2c</td>
<td>-1.2c</td>
<td>0.4c</td>
<td>-1.2c</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>5.3c</td>
<td>-</td>
<td>5.4c</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).
NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).
The APC is significantly different from zero (p<.05).
Statistic could not be calculated.
### SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX

**Blacks, 1992-2002**

<table>
<thead>
<tr>
<th>Site</th>
<th>Incidence(^a)</th>
<th>US Mortality(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>APC</td>
<td>APC</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>-1.0(^c)</td>
<td>-0.9(^c)</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>-3.8(^c)</td>
<td>-3.8(^c)</td>
</tr>
<tr>
<td>Ovary</td>
<td>-1.6(^c)</td>
<td>-1.5(^c)</td>
</tr>
<tr>
<td>Vagina</td>
<td>-2.4</td>
<td>-2.2</td>
</tr>
<tr>
<td>Vulva</td>
<td>-1.9</td>
<td>-1.8</td>
</tr>
<tr>
<td>Other female</td>
<td>-2.0</td>
<td>-1.3</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>-1.4(^c)</td>
<td>-1.9(^c)</td>
</tr>
<tr>
<td>Penis</td>
<td>-1.8</td>
<td>-0.9</td>
</tr>
<tr>
<td>Other male</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary System:</td>
<td>1.1(^c)</td>
<td>0.8</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>2.3(^c)</td>
<td>2.2</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>-4.1(^c)</td>
<td>-2.9</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>-3.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Brain &amp; Nervous System(^d)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>-0.7</td>
<td>0.0</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocrine System:</td>
<td>3.1(^c)</td>
<td>3.5</td>
</tr>
<tr>
<td>Thyroid</td>
<td>3.9(^c)</td>
<td>4.5</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>-1.1</td>
<td>1.8</td>
</tr>
<tr>
<td>Lymphoma:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>0.3</td>
<td>-0.8</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Myeloma</td>
<td>-1.3(^c)</td>
<td>-0.7</td>
</tr>
<tr>
<td>Leukemia:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocytic</td>
<td>-1.4</td>
<td>-1.6</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>-3.2</td>
<td>-3.5</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>-1.8</td>
<td>-3.7</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>-3.8</td>
<td>-3.6</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic</td>
<td>-1.1</td>
<td>-2.1</td>
</tr>
<tr>
<td>Acute myeloid &amp; monocytic</td>
<td>0.8</td>
<td>1.2</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>2.5</td>
<td>4.1</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>-3.0</td>
<td>-4.1</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>0.8</td>
<td>-</td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rappo Sarcoma(^e)</td>
<td>-12.4(^c)</td>
<td>-12.7</td>
</tr>
<tr>
<td>Mesothelioma(^f)</td>
<td>-4.1</td>
<td>-3.7</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>-3.7(^c)</td>
<td>-3.7</td>
</tr>
</tbody>
</table>

\(^a\) The APC is the Annual Percent Change over the time interval.
\(^b\) NCCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
\(^c\) The APC is significantly different from zero (p<.05).
\(^d\) Due to coding changes, Brain & Nervous System mortality are no longer shown separately. This category did not exist in mortality coding until 1999.
\(^e\) Statistic could not be calculated.
Table I-10

AGE DISTRIBUTION (%) OF INCIDENCE CASES BY SITE, 1998-2002

All Races, Both Sexes

<table>
<thead>
<tr>
<th>Site</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>833,460</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>18,840</td>
</tr>
<tr>
<td>Lip</td>
<td>1,627</td>
</tr>
<tr>
<td>Tongue</td>
<td>4,705</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>2,145</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>1,387</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>2,892</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>1,314</td>
</tr>
<tr>
<td>Tonsil</td>
<td>2,389</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>531</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>1,408</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>442</td>
</tr>
<tr>
<td>Digestive System:</td>
<td>159,373</td>
</tr>
<tr>
<td>Esophagus</td>
<td>7,911</td>
</tr>
<tr>
<td>Stomach</td>
<td>15,392</td>
</tr>
<tr>
<td>Small intestine</td>
<td>3,096</td>
</tr>
<tr>
<td>Colon &amp; Rectum:</td>
<td>92,655</td>
</tr>
<tr>
<td>Colon</td>
<td>66,809</td>
</tr>
<tr>
<td>Rectum</td>
<td>25,856</td>
</tr>
<tr>
<td>Colon &amp; Rectum (Male)</td>
<td>46,471</td>
</tr>
<tr>
<td>Colon &amp; Rectum (Female)</td>
<td>46,194</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>2,509</td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>10,942</td>
</tr>
<tr>
<td>Liver</td>
<td>9,548</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>1,394</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>2,141</td>
</tr>
<tr>
<td>Other biliary</td>
<td>2,758</td>
</tr>
<tr>
<td>Pancreas</td>
<td>19,243</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>775</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>1,058</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>883</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>114,250</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>1,191</td>
</tr>
<tr>
<td>Larynx</td>
<td>6,445</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>106,208</td>
</tr>
<tr>
<td>Lung &amp; bronchus (Male)</td>
<td>58,561</td>
</tr>
<tr>
<td>Lung &amp; bronchus (Female)</td>
<td>47,847</td>
</tr>
<tr>
<td>Pleura</td>
<td>63</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>343</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>1,632</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>5,298</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam):</td>
<td>34,843</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>31,589</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>3,254</td>
</tr>
<tr>
<td>Breast (Female)</td>
<td>131,142</td>
</tr>
<tr>
<td>Breast (Female -in situ)</td>
<td>29,912</td>
</tr>
</tbody>
</table>

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia).
### Table I-10 - continued

**Age Distribution (%) of Incidence Cases by Site, 1998-2002**

#### All Races, Both Sexes

<table>
<thead>
<tr>
<th>Site</th>
<th>&lt;20</th>
<th>20-34</th>
<th>35-44</th>
<th>45-54</th>
<th>55-64</th>
<th>65-74</th>
<th>75-84</th>
<th>85+</th>
<th>All Ages</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>0.5</td>
<td>4.7</td>
<td>10.8</td>
<td>19.2</td>
<td>21.9</td>
<td>20.5</td>
<td>16.7</td>
<td>5.6</td>
<td>100.0%</td>
<td>49,631</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>0.2</td>
<td>15.6</td>
<td>26.8</td>
<td>22.7</td>
<td>13.9</td>
<td>10.9</td>
<td>7.1</td>
<td>2.8</td>
<td>100.0%</td>
<td>8,831</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.0</td>
<td>1.5</td>
<td>6.4</td>
<td>18.8</td>
<td>26.6</td>
<td>24.0</td>
<td>17.7</td>
<td>4.9</td>
<td>100.0%</td>
<td>23,096</td>
</tr>
<tr>
<td>Ovary</td>
<td>0.7</td>
<td>3.3</td>
<td>8.2</td>
<td>16.1</td>
<td>16.9</td>
<td>15.2</td>
<td>20.8</td>
<td>18.9</td>
<td>100.0%</td>
<td>461</td>
</tr>
<tr>
<td>Vagina</td>
<td>1.3</td>
<td>3.5</td>
<td>8.4</td>
<td>19.0</td>
<td>20.8</td>
<td>21.1</td>
<td>19.4</td>
<td>6.6</td>
<td>100.0%</td>
<td>13,587</td>
</tr>
<tr>
<td>Vulva</td>
<td>1.1</td>
<td>1.4</td>
<td>7.5</td>
<td>12.9</td>
<td>18.4</td>
<td>24.2</td>
<td>22.2</td>
<td>12.2</td>
<td>100.0%</td>
<td>697</td>
</tr>
<tr>
<td>Other female genital system</td>
<td>0.1</td>
<td>2.9</td>
<td>9.3</td>
<td>14.9</td>
<td>13.5</td>
<td>19.2</td>
<td>25.6</td>
<td>14.5</td>
<td>100.0%</td>
<td>2,227</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td>1.5</td>
<td>9.0</td>
<td>8.5</td>
<td>16.7</td>
<td>21.0</td>
<td>21.3</td>
<td>17.1</td>
<td>4.9</td>
<td>100.0%</td>
<td>732</td>
</tr>
<tr>
<td>Prostate</td>
<td>0.2</td>
<td>1.8</td>
<td>8.2</td>
<td>25.1</td>
<td>36.0</td>
<td>22.4</td>
<td>4.6</td>
<td>100.0%</td>
<td>138,267</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>5.5</td>
<td>46.1</td>
<td>32.3</td>
<td>11.9</td>
<td>2.6</td>
<td>1.0</td>
<td>0.6</td>
<td>0.1</td>
<td>100.0%</td>
<td>5,344</td>
</tr>
<tr>
<td>Penis</td>
<td>0.2</td>
<td>2.1</td>
<td>7.1</td>
<td>10.5</td>
<td>17.7</td>
<td>25.8</td>
<td>26.3</td>
<td>10.3</td>
<td>100.0%</td>
<td>581</td>
</tr>
<tr>
<td>Other male</td>
<td>3.4</td>
<td>2.7</td>
<td>5.7</td>
<td>12.6</td>
<td>19.5</td>
<td>24.9</td>
<td>22.6</td>
<td>8.4</td>
<td>100.0%</td>
<td>261</td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0.7</td>
<td>0.9</td>
<td>3.8</td>
<td>10.8</td>
<td>18.9</td>
<td>27.8</td>
<td>27.8</td>
<td>9.4</td>
<td>100.0%</td>
<td>57,488</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>0.1</td>
<td>0.6</td>
<td>2.4</td>
<td>8.0</td>
<td>16.8</td>
<td>28.8</td>
<td>32.0</td>
<td>11.4</td>
<td>100.0%</td>
<td>35,403</td>
</tr>
<tr>
<td>Ureter</td>
<td>1.8</td>
<td>1.4</td>
<td>6.3</td>
<td>15.0</td>
<td>22.8</td>
<td>25.9</td>
<td>20.2</td>
<td>5.7</td>
<td>100.0%</td>
<td>20,676</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>0.0</td>
<td>0.1</td>
<td>1.0</td>
<td>4.1</td>
<td>15.3</td>
<td>31.2</td>
<td>32.2</td>
<td>12.0</td>
<td>100.0%</td>
<td>888</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>16.1</td>
<td>3.3</td>
<td>7.7</td>
<td>14.8</td>
<td>16.5</td>
<td>19.5</td>
<td>16.2</td>
<td>6.0</td>
<td>100.0%</td>
<td>1,388</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>13.8</td>
<td>10.0</td>
<td>11.7</td>
<td>14.4</td>
<td>15.4</td>
<td>17.1</td>
<td>14.2</td>
<td>3.6</td>
<td>100.0%</td>
<td>11,757</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td>13.4</td>
<td>9.8</td>
<td>11.5</td>
<td>14.3</td>
<td>15.6</td>
<td>17.4</td>
<td>14.5</td>
<td>3.6</td>
<td>100.0%</td>
<td>11,019</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.1</td>
<td>19.4</td>
<td>22.2</td>
<td>21.7</td>
<td>14.6</td>
<td>10.3</td>
<td>6.3</td>
<td>1.5</td>
<td>100.0%</td>
<td>15,804</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>2.3</td>
<td>20.2</td>
<td>23.3</td>
<td>22.1</td>
<td>14.6</td>
<td>10.0</td>
<td>6.0</td>
<td>1.4</td>
<td>100.0%</td>
<td>14,559</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>1.8</td>
<td>4.7</td>
<td>8.6</td>
<td>14.0</td>
<td>17.2</td>
<td>22.8</td>
<td>23.0</td>
<td>7.9</td>
<td>100.0%</td>
<td>34,231</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>12.5</td>
<td>32.9</td>
<td>19.0</td>
<td>12.0</td>
<td>7.8</td>
<td>8.4</td>
<td>5.8</td>
<td>1.6</td>
<td>100.0%</td>
<td>5,180</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0.0</td>
<td>0.6</td>
<td>3.4</td>
<td>11.2</td>
<td>19.0</td>
<td>28.5</td>
<td>27.8</td>
<td>9.4</td>
<td>100.0%</td>
<td>9,708</td>
</tr>
<tr>
<td>Leukemia</td>
<td>11.4</td>
<td>5.2</td>
<td>5.9</td>
<td>9.7</td>
<td>13.9</td>
<td>20.5</td>
<td>23.2</td>
<td>10.1</td>
<td>100.0%</td>
<td>21,859</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>18.9</td>
<td>3.2</td>
<td>4.2</td>
<td>9.3</td>
<td>14.8</td>
<td>19.6</td>
<td>20.7</td>
<td>9.2</td>
<td>100.0%</td>
<td>10,044</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>6.3</td>
<td>7.2</td>
<td>7.0</td>
<td>10.0</td>
<td>13.9</td>
<td>22.4</td>
<td>24.6</td>
<td>8.7</td>
<td>100.0%</td>
<td>6,789</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>2.4</td>
<td>8.6</td>
<td>10.3</td>
<td>12.4</td>
<td>13.4</td>
<td>19.5</td>
<td>23.6</td>
<td>9.7</td>
<td>100.0%</td>
<td>2,675</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>10.4</td>
<td>7.9</td>
<td>6.6</td>
<td>13.9</td>
<td>15.4</td>
<td>18.9</td>
<td>19.1</td>
<td>7.9</td>
<td>100.0%</td>
<td>482</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>4.3</td>
<td>2.5</td>
<td>5.0</td>
<td>6.5</td>
<td>10.8</td>
<td>22.6</td>
<td>36.2</td>
<td>12.2</td>
<td>100.0%</td>
<td>279</td>
</tr>
<tr>
<td>Kaposi Sarcoma</td>
<td>0.1</td>
<td>24.1</td>
<td>39.4</td>
<td>16.4</td>
<td>5.1</td>
<td>4.9</td>
<td>6.2</td>
<td>3.9</td>
<td>100.0%</td>
<td>1,729</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>0.1</td>
<td>1.0</td>
<td>2.6</td>
<td>7.5</td>
<td>15.1</td>
<td>29.6</td>
<td>35.6</td>
<td>8.4</td>
<td>100.0%</td>
<td>1,776</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>0.4</td>
<td>1.1</td>
<td>3.3</td>
<td>9.7</td>
<td>15.6</td>
<td>24.1</td>
<td>29.9</td>
<td>15.9</td>
<td>100.0%</td>
<td>18,351</td>
</tr>
</tbody>
</table>

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose–Monterey, Los Angeles, Alaska Native Registry, Rural Georgia).
### Table I-11

#### MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS*, 1998-2002

By Primary Cancer Site, Race and Sex

<table>
<thead>
<tr>
<th>Site</th>
<th>All Races</th>
<th></th>
<th></th>
<th></th>
<th>Whites</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Blacks</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>67.0</td>
<td>68.0</td>
<td>66.0</td>
<td></td>
<td>68.0</td>
<td>68.0</td>
<td>67.0</td>
<td></td>
<td>64.0</td>
<td>64.0</td>
<td>62.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>63.0</td>
<td>61.0</td>
<td>66.0</td>
<td></td>
<td>64.0</td>
<td>62.0</td>
<td>68.0</td>
<td></td>
<td>57.0</td>
<td>57.0</td>
<td>56.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lip</td>
<td>70.0</td>
<td>68.0</td>
<td>74.0</td>
<td></td>
<td>70.0</td>
<td>68.0</td>
<td>75.0</td>
<td></td>
<td>56.5</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tongue</td>
<td>62.0</td>
<td>60.0</td>
<td>65.0</td>
<td></td>
<td>62.0</td>
<td>61.0</td>
<td>66.0</td>
<td></td>
<td>57.0</td>
<td>57.0</td>
<td>59.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivary gland</td>
<td>63.0</td>
<td>66.0</td>
<td>60.0</td>
<td></td>
<td>65.0</td>
<td>67.0</td>
<td>62.5</td>
<td></td>
<td>55.5</td>
<td>56.5</td>
<td>53.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>63.0</td>
<td>61.0</td>
<td>67.0</td>
<td></td>
<td>64.0</td>
<td>62.0</td>
<td>68.0</td>
<td></td>
<td>56.5</td>
<td>57.0</td>
<td>56.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>68.0</td>
<td>65.0</td>
<td>72.0</td>
<td></td>
<td>69.0</td>
<td>66.0</td>
<td>73.0</td>
<td></td>
<td>58.0</td>
<td>58.0</td>
<td>56.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>oral cavity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>53.0</td>
<td>54.0</td>
<td>53.0</td>
<td></td>
<td>58.0</td>
<td>57.0</td>
<td>62.0</td>
<td></td>
<td>47.5</td>
<td>50.0</td>
<td>42.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tonsil</td>
<td>57.0</td>
<td>56.0</td>
<td>61.0</td>
<td></td>
<td>57.0</td>
<td>56.0</td>
<td>62.0</td>
<td></td>
<td>56.0</td>
<td>56.0</td>
<td>55.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>63.0</td>
<td>62.0</td>
<td>67.5</td>
<td></td>
<td>65.0</td>
<td>63.0</td>
<td>68.0</td>
<td></td>
<td>60.0</td>
<td>59.0</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>66.0</td>
<td>65.0</td>
<td>68.0</td>
<td></td>
<td>67.0</td>
<td>66.0</td>
<td>69.0</td>
<td></td>
<td>59.0</td>
<td>59.5</td>
<td>57.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>66.0</td>
<td>64.0</td>
<td>69.0</td>
<td></td>
<td>66.0</td>
<td>65.0</td>
<td>70.0</td>
<td></td>
<td>62.0</td>
<td>60.0</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; Intrahep</td>
<td>66.0</td>
<td>64.0</td>
<td>71.0</td>
<td></td>
<td>68.0</td>
<td>65.0</td>
<td>72.0</td>
<td></td>
<td>60.0</td>
<td>58.0</td>
<td>66.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>65.5</td>
<td>63.0</td>
<td>70.0</td>
<td></td>
<td>67.0</td>
<td>65.0</td>
<td>72.0</td>
<td></td>
<td>59.0</td>
<td>57.0</td>
<td>66.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>71.0</td>
<td>70.0</td>
<td>74.0</td>
<td></td>
<td>72.0</td>
<td>70.0</td>
<td>75.0</td>
<td></td>
<td>66.0</td>
<td>66.5</td>
<td>66.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallbladder</td>
<td>73.0</td>
<td>73.0</td>
<td>73.0</td>
<td></td>
<td>73.0</td>
<td>74.0</td>
<td>73.0</td>
<td></td>
<td>70.0</td>
<td>70.0</td>
<td>70.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other biliary</td>
<td>73.0</td>
<td>71.0</td>
<td>74.0</td>
<td></td>
<td>73.0</td>
<td>72.0</td>
<td>75.0</td>
<td></td>
<td>70.0</td>
<td>67.0</td>
<td>73.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>72.0</td>
<td>70.0</td>
<td>74.0</td>
<td></td>
<td>73.0</td>
<td>70.0</td>
<td>75.0</td>
<td></td>
<td>68.0</td>
<td>65.5</td>
<td>71.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>60.0</td>
<td>60.0</td>
<td>61.5</td>
<td></td>
<td>61.0</td>
<td>60.0</td>
<td>63.5</td>
<td></td>
<td>54.0</td>
<td>53.0</td>
<td>55.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>67.0</td>
<td>63.0</td>
<td>68.0</td>
<td></td>
<td>68.0</td>
<td>64.0</td>
<td>68.0</td>
<td></td>
<td>66.0</td>
<td>-</td>
<td>66.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other digestive system</td>
<td>73.0</td>
<td>71.0</td>
<td>75.0</td>
<td></td>
<td>73.0</td>
<td>72.0</td>
<td>75.0</td>
<td></td>
<td>69.0</td>
<td>63.0</td>
<td>72.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>70.0</td>
<td>70.0</td>
<td>70.0</td>
<td></td>
<td>71.0</td>
<td>70.0</td>
<td>71.0</td>
<td></td>
<td>66.0</td>
<td>65.0</td>
<td>67.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>64.0</td>
<td>61.0</td>
<td>67.0</td>
<td></td>
<td>64.0</td>
<td>61.0</td>
<td>67.0</td>
<td></td>
<td>62.0</td>
<td>61.0</td>
<td>62.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td>65.0</td>
<td>65.0</td>
<td>65.0</td>
<td></td>
<td>66.0</td>
<td>66.0</td>
<td>66.0</td>
<td></td>
<td>62.0</td>
<td>62.0</td>
<td>62.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>70.0</td>
<td>70.0</td>
<td>71.0</td>
<td></td>
<td>71.0</td>
<td>71.0</td>
<td>71.0</td>
<td></td>
<td>66.0</td>
<td>66.0</td>
<td>67.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleura</td>
<td>67.0</td>
<td>67.0</td>
<td>-</td>
<td></td>
<td>66.0</td>
<td>65.0</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>45.0</td>
<td>38.5</td>
<td>59.0</td>
<td></td>
<td>42.0</td>
<td>37.0</td>
<td>57.0</td>
<td></td>
<td>56.5</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>38.0</td>
<td>34.0</td>
<td>42.0</td>
<td></td>
<td>39.0</td>
<td>36.0</td>
<td>43.0</td>
<td></td>
<td>32.0</td>
<td>29.0</td>
<td>33.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>55.0</td>
<td>55.0</td>
<td>56.0</td>
<td></td>
<td>57.0</td>
<td>57.0</td>
<td>56.0</td>
<td></td>
<td>48.0</td>
<td>44.0</td>
<td>52.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam):</td>
<td>58.0</td>
<td>61.0</td>
<td>54.0</td>
<td></td>
<td>58.0</td>
<td>62.0</td>
<td>54.0</td>
<td></td>
<td>53.0</td>
<td>56.0</td>
<td>51.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>57.0</td>
<td>61.0</td>
<td>53.0</td>
<td></td>
<td>57.0</td>
<td>61.0</td>
<td>53.0</td>
<td></td>
<td>60.0</td>
<td>61.0</td>
<td>56.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>68.0</td>
<td>70.0</td>
<td>65.0</td>
<td></td>
<td>70.0</td>
<td>71.0</td>
<td>68.0</td>
<td></td>
<td>47.0</td>
<td>47.0</td>
<td>46.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>61.0</td>
<td>67.0</td>
<td>61.0</td>
<td></td>
<td>62.0</td>
<td>68.0</td>
<td>62.0</td>
<td></td>
<td>57.0</td>
<td>60.5</td>
<td>57.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>58.0</td>
<td>58.5</td>
<td>58.0</td>
<td></td>
<td>58.0</td>
<td>59.0</td>
<td>58.0</td>
<td></td>
<td>57.0</td>
<td>-</td>
<td>57.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
- Statistic could not be calculated. Less than 25 cases were diagnosed during the time interval.
Table I-11 - continued  
MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS*, 1998-2002  
By Primary Cancer Site, Race and Sex

<table>
<thead>
<tr>
<th>Site</th>
<th>All Races</th>
<th></th>
<th></th>
<th>Whites</th>
<th></th>
<th></th>
<th></th>
<th>Blacks</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vulva</td>
<td>70.0</td>
<td>70.0</td>
<td>71.0</td>
<td>71.0</td>
<td>70.0</td>
<td>72.0</td>
<td>65.0</td>
<td>65.0</td>
<td>67.0</td>
<td></td>
</tr>
<tr>
<td>Other female</td>
<td>61.0</td>
<td>61.0</td>
<td>63.0</td>
<td>63.0</td>
<td>61.0</td>
<td>63.0</td>
<td>49.0</td>
<td>49.0</td>
<td>50.0</td>
<td></td>
</tr>
<tr>
<td>Male Genital System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>69.0</td>
<td>69.0</td>
<td>69.0</td>
<td>69.0</td>
<td>66.0</td>
<td>66.0</td>
<td>70.0</td>
<td>70.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>34.0</td>
<td>34.0</td>
<td>34.0</td>
<td>34.0</td>
<td>35.0</td>
<td>35.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penis</td>
<td>69.0</td>
<td>69.0</td>
<td>69.0</td>
<td>69.0</td>
<td>70.0</td>
<td>70.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other male</td>
<td>67.0</td>
<td>67.0</td>
<td>68.0</td>
<td>68.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>73.0</td>
<td>72.0</td>
<td>74.0</td>
<td>73.0</td>
<td>72.0</td>
<td>74.0</td>
<td>65.0</td>
<td>65.0</td>
<td>73.0</td>
<td></td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>65.0</td>
<td>64.0</td>
<td>67.0</td>
<td>66.0</td>
<td>65.0</td>
<td>68.0</td>
<td>61.0</td>
<td>60.0</td>
<td>62.0</td>
<td></td>
</tr>
<tr>
<td>Ureter</td>
<td>74.0</td>
<td>72.0</td>
<td>76.0</td>
<td>74.0</td>
<td>72.0</td>
<td>77.0</td>
<td>69.0</td>
<td>65.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other urinary system</td>
<td>72.0</td>
<td>72.0</td>
<td>71.0</td>
<td>73.0</td>
<td>73.0</td>
<td>74.0</td>
<td>66.0</td>
<td>67.5</td>
<td>63.0</td>
<td></td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>59.0</td>
<td>57.0</td>
<td>61.0</td>
<td>60.0</td>
<td>58.0</td>
<td>62.0</td>
<td>3.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain &amp; Nervous System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain</td>
<td>55.0</td>
<td>54.0</td>
<td>56.0</td>
<td>56.0</td>
<td>55.0</td>
<td>57.0</td>
<td>47.0</td>
<td>46.0</td>
<td>48.5</td>
<td></td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td>48.0</td>
<td>45.0</td>
<td>49.0</td>
<td>47.0</td>
<td>45.0</td>
<td>49.0</td>
<td>49.0</td>
<td>48.5</td>
<td>49.0</td>
<td></td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>46.0</td>
<td>50.5</td>
<td>45.0</td>
<td>46.0</td>
<td>51.0</td>
<td>45.0</td>
<td>49.0</td>
<td>51.0</td>
<td>48.0</td>
<td></td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>48.0</td>
<td>46.0</td>
<td>49.0</td>
<td>48.0</td>
<td>47.0</td>
<td>50.0</td>
<td>49.0</td>
<td>47.0</td>
<td>49.0</td>
<td></td>
</tr>
<tr>
<td>Lymphomas:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>37.0</td>
<td>38.0</td>
<td>35.0</td>
<td>37.0</td>
<td>39.0</td>
<td>35.0</td>
<td>35.0</td>
<td>37.0</td>
<td>31.5</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>66.0</td>
<td>64.0</td>
<td>69.0</td>
<td>67.0</td>
<td>65.0</td>
<td>70.0</td>
<td>55.0</td>
<td>52.0</td>
<td>58.0</td>
<td></td>
</tr>
<tr>
<td>Myeloma</td>
<td>70.0</td>
<td>69.0</td>
<td>72.0</td>
<td>71.0</td>
<td>70.0</td>
<td>73.0</td>
<td>67.0</td>
<td>66.0</td>
<td>68.0</td>
<td></td>
</tr>
<tr>
<td>Leukemia:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>61.5</td>
<td>63.5</td>
<td>60.0</td>
<td>64.0</td>
<td>65.0</td>
<td>69.0</td>
<td>59.0</td>
<td>60.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloid &amp; monocytic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td>74.0</td>
<td>73.0</td>
<td>76.0</td>
<td>74.5</td>
<td>73.0</td>
<td>76.0</td>
<td>74.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaposi Sarcoma</td>
<td>40.0</td>
<td>40.0</td>
<td>76.0</td>
<td>42.0</td>
<td>41.0</td>
<td>79.0</td>
<td>37.0</td>
<td>37.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>73.0</td>
<td>74.0</td>
<td>70.0</td>
<td>74.0</td>
<td>74.0</td>
<td>71.0</td>
<td>68.0</td>
<td>71.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>73.0</td>
<td>71.0</td>
<td>75.0</td>
<td>74.0</td>
<td>72.0</td>
<td>76.0</td>
<td>67.0</td>
<td>64.0</td>
<td>70.0</td>
<td></td>
</tr>
</tbody>
</table>

* SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).  
- Statistic could not be calculated. Less than 25 cases were diagnosed during the time interval.
<table>
<thead>
<tr>
<th>Site</th>
<th>&lt;20</th>
<th>20-34</th>
<th>35-44</th>
<th>45-54</th>
<th>55-64</th>
<th>65-74</th>
<th>75-84</th>
<th>85+</th>
<th>All Ages</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>0.4</td>
<td>0.9</td>
<td>3.0</td>
<td>8.7</td>
<td>16.3</td>
<td>27.2</td>
<td>29.7</td>
<td>13.8</td>
<td>100.00%</td>
<td>2,755,502</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>0.2</td>
<td>0.9</td>
<td>3.7</td>
<td>13.9</td>
<td>22.3</td>
<td>25.6</td>
<td>22.5</td>
<td>10.9</td>
<td>100.00%</td>
<td>38,381</td>
</tr>
<tr>
<td>Lip</td>
<td>0.3</td>
<td>1.1</td>
<td>3.3</td>
<td>7.2</td>
<td>12.5</td>
<td>20.6</td>
<td>29.8</td>
<td>25.1</td>
<td>100.00%</td>
<td>359</td>
</tr>
<tr>
<td>Tongue</td>
<td>0.1</td>
<td>1.5</td>
<td>4.7</td>
<td>14.7</td>
<td>23.3</td>
<td>24.6</td>
<td>21.6</td>
<td>9.6</td>
<td>100.00%</td>
<td>8,974</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.1</td>
<td>0.3</td>
<td>3.8</td>
<td>4.6</td>
<td>15.5</td>
<td>22.2</td>
<td>18.1</td>
<td>3.1</td>
<td>100.00%</td>
<td>3,121</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0.0</td>
<td>0.0</td>
<td>3.5</td>
<td>5.7</td>
<td>25.7</td>
<td>29.7</td>
<td>18.4</td>
<td>6.9</td>
<td>100.00%</td>
<td>821</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>0.5</td>
<td>0.5</td>
<td>2.1</td>
<td>10.2</td>
<td>16.8</td>
<td>24.3</td>
<td>26.4</td>
<td>19.3</td>
<td>100.00%</td>
<td>6,120</td>
</tr>
<tr>
<td>oral cavity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>1.1</td>
<td>3.4</td>
<td>8.9</td>
<td>19.2</td>
<td>22.6</td>
<td>21.7</td>
<td>17.6</td>
<td>5.6</td>
<td>100.00%</td>
<td>3,242</td>
</tr>
<tr>
<td>Tonsil</td>
<td>0.0</td>
<td>0.3</td>
<td>4.8</td>
<td>21.0</td>
<td>27.3</td>
<td>25.7</td>
<td>16.7</td>
<td>4.3</td>
<td>100.00%</td>
<td>2,881</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.1</td>
<td>0.1</td>
<td>2.5</td>
<td>15.7</td>
<td>24.6</td>
<td>27.1</td>
<td>21.3</td>
<td>8.6</td>
<td>100.00%</td>
<td>2,921</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.0</td>
<td>0.1</td>
<td>2.3</td>
<td>13.5</td>
<td>28.5</td>
<td>30.8</td>
<td>19.1</td>
<td>5.8</td>
<td>100.00%</td>
<td>1,806</td>
</tr>
<tr>
<td>Other oral cavity</td>
<td>0.0</td>
<td>0.2</td>
<td>2.3</td>
<td>12.5</td>
<td>24.2</td>
<td>28.6</td>
<td>23.4</td>
<td>8.7</td>
<td>100.00%</td>
<td>7,845</td>
</tr>
<tr>
<td>&amp; pharynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>0.5</td>
<td>0.8</td>
<td>3.2</td>
<td>13.0</td>
<td>17.4</td>
<td>26.8</td>
<td>27.4</td>
<td>10.9</td>
<td>100.00%</td>
<td>65,077</td>
</tr>
<tr>
<td>Liver</td>
<td>0.6</td>
<td>0.8</td>
<td>3.3</td>
<td>14.2</td>
<td>17.7</td>
<td>27.0</td>
<td>26.5</td>
<td>9.9</td>
<td>100.00%</td>
<td>51,470</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>0.0</td>
<td>0.7</td>
<td>2.8</td>
<td>8.6</td>
<td>16.1</td>
<td>26.4</td>
<td>30.9</td>
<td>14.6</td>
<td>100.00%</td>
<td>13,607</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>0.0</td>
<td>0.1</td>
<td>1.9</td>
<td>7.2</td>
<td>14.1</td>
<td>27.1</td>
<td>33.1</td>
<td>16.5</td>
<td>100.00%</td>
<td>9,888</td>
</tr>
<tr>
<td>Other biliary</td>
<td>0.1</td>
<td>0.2</td>
<td>3.8</td>
<td>9.6</td>
<td>11.3</td>
<td>24.0</td>
<td>25.7</td>
<td>12.8</td>
<td>100.00%</td>
<td>7,842</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.0</td>
<td>0.2</td>
<td>2.0</td>
<td>8.0</td>
<td>16.2</td>
<td>27.9</td>
<td>31.5</td>
<td>14.3</td>
<td>100.00%</td>
<td>146,812</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>0.5</td>
<td>2.3</td>
<td>4.8</td>
<td>9.7</td>
<td>17.5</td>
<td>24.9</td>
<td>28.8</td>
<td>11.6</td>
<td>100.00%</td>
<td>1,200</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>0.0</td>
<td>0.5</td>
<td>1.9</td>
<td>6.3</td>
<td>12.4</td>
<td>22.8</td>
<td>31.8</td>
<td>24.3</td>
<td>100.00%</td>
<td>4,287</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>0.0</td>
<td>0.1</td>
<td>1.8</td>
<td>7.7</td>
<td>19.3</td>
<td>33.4</td>
<td>29.4</td>
<td>8.2</td>
<td>100.00%</td>
<td>799,882</td>
</tr>
<tr>
<td>Larynx</td>
<td>0.5</td>
<td>1.8</td>
<td>6.8</td>
<td>13.3</td>
<td>17.7</td>
<td>22.3</td>
<td>24.3</td>
<td>13.5</td>
<td>100.00%</td>
<td>2,292</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>0.0</td>
<td>0.1</td>
<td>2.0</td>
<td>11.1</td>
<td>23.6</td>
<td>31.4</td>
<td>24.6</td>
<td>7.1</td>
<td>100.00%</td>
<td>19,061</td>
</tr>
<tr>
<td>Lung &amp; bronchus (Male)</td>
<td>0.0</td>
<td>0.1</td>
<td>1.8</td>
<td>7.6</td>
<td>19.2</td>
<td>33.5</td>
<td>29.5</td>
<td>8.2</td>
<td>100.00%</td>
<td>775,558</td>
</tr>
<tr>
<td>Lung &amp; bronchus (Female)</td>
<td>0.0</td>
<td>0.1</td>
<td>1.6</td>
<td>7.8</td>
<td>20.0</td>
<td>34.5</td>
<td>28.8</td>
<td>7.1</td>
<td>100.00%</td>
<td>451,690</td>
</tr>
<tr>
<td>Pleura</td>
<td>0.2</td>
<td>0.1</td>
<td>4.9</td>
<td>14.9</td>
<td>30.8</td>
<td>36.9</td>
<td>16.9</td>
<td>11.1</td>
<td>100.00%</td>
<td>1,625</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>1.7</td>
<td>5.1</td>
<td>6.5</td>
<td>11.7</td>
<td>16.3</td>
<td>25.6</td>
<td>24.1</td>
<td>9.0</td>
<td>100.00%</td>
<td>1,346</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>4.0</td>
<td>6.7</td>
<td>8.4</td>
<td>13.5</td>
<td>16.2</td>
<td>20.7</td>
<td>21.2</td>
<td>9.3</td>
<td>100.00%</td>
<td>18,606</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam):</td>
<td>0.1</td>
<td>2.5</td>
<td>7.0</td>
<td>13.8</td>
<td>16.8</td>
<td>22.4</td>
<td>23.8</td>
<td>13.5</td>
<td>100.00%</td>
<td>48,786</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>0.1</td>
<td>3.1</td>
<td>8.5</td>
<td>15.5</td>
<td>17.5</td>
<td>22.5</td>
<td>22.5</td>
<td>10.3</td>
<td>100.00%</td>
<td>37,121</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>0.0</td>
<td>0.6</td>
<td>2.3</td>
<td>8.4</td>
<td>14.7</td>
<td>22.2</td>
<td>28.1</td>
<td>23.6</td>
<td>100.00%</td>
<td>11,665</td>
</tr>
<tr>
<td>Breast (Female)</td>
<td>0.0</td>
<td>1.1</td>
<td>6.8</td>
<td>15.3</td>
<td>18.1</td>
<td>21.4</td>
<td>23.0</td>
<td>14.3</td>
<td>100.00%</td>
<td>207,660</td>
</tr>
</tbody>
</table>

Source: NCHS public use data file for the total US.
Table I-12 - continued

AGE DISTRIBUTION (%) OF DEATHS BY SITE, 1998-2002

All Races, Both Sexes

<table>
<thead>
<tr>
<th>Site</th>
<th>&lt;20</th>
<th>20-34</th>
<th>35-44</th>
<th>45-54</th>
<th>55-64</th>
<th>65-74</th>
<th>75-84</th>
<th>85+</th>
<th>All Ages</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female Genital System:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>0.0</td>
<td>1.5</td>
<td>5.2</td>
<td>11.9</td>
<td>17.1</td>
<td>24.4</td>
<td>26.8</td>
<td>13.0</td>
<td>100.0%</td>
<td>131,787</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>0.0</td>
<td>5.8</td>
<td>17.1</td>
<td>22.4</td>
<td>17.6</td>
<td>15.8</td>
<td>13.9</td>
<td>7.5</td>
<td>100.0%</td>
<td>20,788</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.0</td>
<td>0.3</td>
<td>1.7</td>
<td>6.6</td>
<td>17.0</td>
<td>29.5</td>
<td>30.6</td>
<td>14.3</td>
<td>100.0%</td>
<td>15,790</td>
</tr>
<tr>
<td>Ovary</td>
<td>0.1</td>
<td>0.8</td>
<td>3.4</td>
<td>11.3</td>
<td>17.9</td>
<td>25.9</td>
<td>28.7</td>
<td>11.9</td>
<td>100.0%</td>
<td>70,173</td>
</tr>
<tr>
<td>Vagina</td>
<td>0.0</td>
<td>0.6</td>
<td>3.8</td>
<td>10.2</td>
<td>11.7</td>
<td>20.8</td>
<td>27.8</td>
<td>25.1</td>
<td>100.0%</td>
<td>1,997</td>
</tr>
<tr>
<td>Vulva</td>
<td>0.0</td>
<td>0.5</td>
<td>2.7</td>
<td>5.3</td>
<td>8.7</td>
<td>17.9</td>
<td>33.9</td>
<td>30.9</td>
<td>100.0%</td>
<td>3,803</td>
</tr>
<tr>
<td>Other female</td>
<td>0.0</td>
<td>2.1</td>
<td>3.1</td>
<td>10.4</td>
<td>18.1</td>
<td>25.7</td>
<td>28.2</td>
<td>12.3</td>
<td>100.0%</td>
<td>1,916</td>
</tr>
<tr>
<td><strong>Male Genital System:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>0.0</td>
<td>0.4</td>
<td>0.5</td>
<td>1.5</td>
<td>6.4</td>
<td>21.9</td>
<td>41.7</td>
<td>27.5</td>
<td>100.0%</td>
<td>159,208</td>
</tr>
<tr>
<td>Testis</td>
<td>2.1</td>
<td>33.5</td>
<td>28.8</td>
<td>15.7</td>
<td>7.5</td>
<td>5.8</td>
<td>4.6</td>
<td>1.9</td>
<td>100.0%</td>
<td>1,814</td>
</tr>
<tr>
<td>Penis</td>
<td>0.0</td>
<td>0.7</td>
<td>4.7</td>
<td>11.3</td>
<td>18.4</td>
<td>25.1</td>
<td>26.2</td>
<td>13.5</td>
<td>100.0%</td>
<td>1,010</td>
</tr>
<tr>
<td>Other male</td>
<td>0.0</td>
<td>4.0</td>
<td>6.0</td>
<td>7.5</td>
<td>10.4</td>
<td>18.4</td>
<td>33.3</td>
<td>20.4</td>
<td>100.0%</td>
<td>201</td>
</tr>
<tr>
<td><strong>Urinary System:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0.3</td>
<td>0.3</td>
<td>1.9</td>
<td>7.1</td>
<td>14.5</td>
<td>25.5</td>
<td>32.3</td>
<td>18.2</td>
<td>100.0%</td>
<td>122,131</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>0.0</td>
<td>0.1</td>
<td>0.9</td>
<td>3.8</td>
<td>10.3</td>
<td>23.8</td>
<td>36.8</td>
<td>24.3</td>
<td>100.0%</td>
<td>60,521</td>
</tr>
<tr>
<td>Ureter</td>
<td>0.5</td>
<td>0.5</td>
<td>2.9</td>
<td>10.6</td>
<td>19.0</td>
<td>27.3</td>
<td>27.4</td>
<td>11.8</td>
<td>100.0%</td>
<td>58,579</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>0.0</td>
<td>0.2</td>
<td>2.2</td>
<td>7.0</td>
<td>11.9</td>
<td>23.8</td>
<td>35.7</td>
<td>19.3</td>
<td>100.0%</td>
<td>1,468</td>
</tr>
<tr>
<td><strong>Eye &amp; Orbit</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain &amp; Nervous System</td>
<td>5.1</td>
<td>1.5</td>
<td>4.9</td>
<td>10.7</td>
<td>18.1</td>
<td>21.0</td>
<td>25.0</td>
<td>13.8</td>
<td>100.0%</td>
<td>1,207</td>
</tr>
<tr>
<td><strong>Endocrine System:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>4.3</td>
<td>4.2</td>
<td>8.3</td>
<td>15.2</td>
<td>19.2</td>
<td>23.9</td>
<td>19.5</td>
<td>5.5</td>
<td>100.0%</td>
<td>63,525</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>8.4</td>
<td>2.8</td>
<td>5.1</td>
<td>10.2</td>
<td>15.2</td>
<td>22.2</td>
<td>24.8</td>
<td>11.2</td>
<td>100.0%</td>
<td>10,981</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>2.5</td>
<td>16.2</td>
<td>12.2</td>
<td>12.6</td>
<td>11.9</td>
<td>18.1</td>
<td>19.2</td>
<td>7.4</td>
<td>100.0%</td>
<td>6,676</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>1.8</td>
<td>1.0</td>
<td>3.5</td>
<td>7.7</td>
<td>13.9</td>
<td>24.9</td>
<td>32.9</td>
<td>14.9</td>
<td>100.0%</td>
<td>113,180</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloma</td>
<td>0.0</td>
<td>0.1</td>
<td>1.4</td>
<td>6.3</td>
<td>14.8</td>
<td>28.9</td>
<td>34.5</td>
<td>13.9</td>
<td>100.0%</td>
<td>53,100</td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>3.3</td>
<td>3.5</td>
<td>3.9</td>
<td>6.7</td>
<td>11.8</td>
<td>23.4</td>
<td>31.1</td>
<td>16.4</td>
<td>100.0%</td>
<td>106,050</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>5.1</td>
<td>3.7</td>
<td>2.7</td>
<td>5.0</td>
<td>10.2</td>
<td>21.3</td>
<td>30.8</td>
<td>21.3</td>
<td>100.0%</td>
<td>30,785</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>22.2</td>
<td>15.7</td>
<td>9.6</td>
<td>10.7</td>
<td>11.1</td>
<td>12.9</td>
<td>12.4</td>
<td>5.6</td>
<td>100.0%</td>
<td>7,057</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>0.0</td>
<td>0.1</td>
<td>0.6</td>
<td>3.1</td>
<td>9.8</td>
<td>24.0</td>
<td>36.2</td>
<td>26.2</td>
<td>100.0%</td>
<td>21,777</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>0.8</td>
<td>0.4</td>
<td>1.5</td>
<td>4.9</td>
<td>11.0</td>
<td>21.8</td>
<td>36.1</td>
<td>23.5</td>
<td>100.0%</td>
<td>3,551</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>2.5</td>
<td>3.2</td>
<td>5.1</td>
<td>8.6</td>
<td>13.7</td>
<td>25.2</td>
<td>29.7</td>
<td>11.4</td>
<td>100.0%</td>
<td>48,940</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>2.9</td>
<td>3.7</td>
<td>4.8</td>
<td>8.4</td>
<td>13.9</td>
<td>26.1</td>
<td>29.8</td>
<td>10.3</td>
<td>100.0%</td>
<td>36,593</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>1.1</td>
<td>5.0</td>
<td>7.6</td>
<td>11.3</td>
<td>14.2</td>
<td>21.9</td>
<td>26.2</td>
<td>12.7</td>
<td>100.0%</td>
<td>8,910</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>3.7</td>
<td>2.4</td>
<td>4.3</td>
<td>5.3</td>
<td>11.3</td>
<td>22.3</td>
<td>31.8</td>
<td>18.9</td>
<td>100.0%</td>
<td>628</td>
</tr>
<tr>
<td>Other:</td>
<td>1.4</td>
<td>1.0</td>
<td>1.6</td>
<td>3.3</td>
<td>10.0</td>
<td>24.8</td>
<td>38.9</td>
<td>19.0</td>
<td>100.0%</td>
<td>2,609</td>
</tr>
<tr>
<td>Other acute</td>
<td>2.6</td>
<td>2.6</td>
<td>2.9</td>
<td>5.3</td>
<td>10.0</td>
<td>22.4</td>
<td>34.3</td>
<td>20.0</td>
<td>100.0%</td>
<td>26,325</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>3.4</td>
<td>2.3</td>
<td>2.6</td>
<td>4.9</td>
<td>9.5</td>
<td>20.6</td>
<td>33.4</td>
<td>23.4</td>
<td>100.0%</td>
<td>13,827</td>
</tr>
<tr>
<td>All Races, Both Sexes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: NCHS public use data file for the total US.
<table>
<thead>
<tr>
<th>Site</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Sites</td>
<td>72.0</td>
<td>72.0</td>
<td>73.0</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lip</td>
<td>68.0</td>
<td>66.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Tongue</td>
<td>76.0</td>
<td>74.0</td>
<td>83.0</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>67.0</td>
<td>64.0</td>
<td>73.0</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>66.0</td>
<td>63.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>73.0</td>
<td>68.0</td>
<td>79.0</td>
</tr>
<tr>
<td>oral cavity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>62.0</td>
<td>60.0</td>
<td>66.0</td>
</tr>
<tr>
<td>Tonsil</td>
<td>63.0</td>
<td>61.0</td>
<td>69.0</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>67.0</td>
<td>65.0</td>
<td>73.0</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>66.0</td>
<td>66.0</td>
<td>70.0</td>
</tr>
<tr>
<td>Other oral cavity</td>
<td>69.0</td>
<td>67.0</td>
<td>72.0</td>
</tr>
<tr>
<td>&amp; pharynx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>70.0</td>
<td>69.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Stomach</td>
<td>74.0</td>
<td>72.0</td>
<td>76.0</td>
</tr>
<tr>
<td>Small intestine</td>
<td>71.0</td>
<td>70.0</td>
<td>73.0</td>
</tr>
<tr>
<td>Colon &amp; Rectum</td>
<td>75.0</td>
<td>73.0</td>
<td>77.0</td>
</tr>
<tr>
<td>Anus, anal canal &amp; anorectum</td>
<td>67.0</td>
<td>63.0</td>
<td>69.0</td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>71.0</td>
<td>68.0</td>
<td>75.0</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>70.0</td>
<td>67.0</td>
<td>75.0</td>
</tr>
<tr>
<td>Other biliary</td>
<td>77.0</td>
<td>75.0</td>
<td>78.0</td>
</tr>
<tr>
<td>Pancreas</td>
<td>73.0</td>
<td>71.0</td>
<td>75.0</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>71.0</td>
<td>70.0</td>
<td>73.0</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>71.0</td>
<td>68.0</td>
<td>71.0</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>77.0</td>
<td>74.0</td>
<td>80.0</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>71.0</td>
<td>71.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Larynx</td>
<td>70.0</td>
<td>66.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>69.0</td>
<td>68.0</td>
<td>70.0</td>
</tr>
<tr>
<td>Pleura</td>
<td>71.0</td>
<td>71.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>74.0</td>
<td>74.0</td>
<td>75.5</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>71.0</td>
<td>55.0</td>
<td>65.5</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>65.0</td>
<td>64.0</td>
<td>67.0</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam):</td>
<td>69.0</td>
<td>68.0</td>
<td>71.0</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>67.0</td>
<td>67.0</td>
<td>68.0</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>75.0</td>
<td>73.0</td>
<td>80.0</td>
</tr>
<tr>
<td>Breast</td>
<td>69.0</td>
<td>71.0</td>
<td>69.0</td>
</tr>
</tbody>
</table>
Table I-13 - continued

<table>
<thead>
<tr>
<th>Site</th>
<th>All Races</th>
<th>White</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td>71.0 -</td>
<td>71.0</td>
<td>71.0</td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>57.0 -</td>
<td>57.0</td>
<td>57.0</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>73.0 -</td>
<td>73.0</td>
<td>73.0</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>74.0 -</td>
<td>74.0</td>
<td>75.0</td>
</tr>
<tr>
<td>Ovary</td>
<td>71.0 -</td>
<td>71.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Vagina</td>
<td>76.0 -</td>
<td>76.0</td>
<td>77.0</td>
</tr>
<tr>
<td>Vulva</td>
<td>79.0 -</td>
<td>79.0</td>
<td>80.0</td>
</tr>
<tr>
<td>Other female genital system</td>
<td>71.0 -</td>
<td>71.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td>79.0 -</td>
<td>79.0</td>
<td>80.0</td>
</tr>
<tr>
<td>Prostate</td>
<td>79.0 -</td>
<td>79.0</td>
<td>80.0</td>
</tr>
<tr>
<td>Testis</td>
<td>39.5 -</td>
<td>39.5</td>
<td>40.0</td>
</tr>
<tr>
<td>Penis</td>
<td>70.0 -</td>
<td>71.0</td>
<td>71.0</td>
</tr>
<tr>
<td>Other male</td>
<td>75.0 -</td>
<td>76.0</td>
<td>76.0</td>
</tr>
<tr>
<td>Urinary System:</td>
<td>75.0</td>
<td>7</td>
<td>77.0</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>78.0</td>
<td>80.0</td>
<td>80.0</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>71.0</td>
<td>74.0</td>
<td>71.0</td>
</tr>
<tr>
<td>Ureter</td>
<td>76.0</td>
<td>77.0</td>
<td>76.0</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>76.0</td>
<td>77.0</td>
<td>77.0</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>70.0</td>
<td>68.0</td>
<td>73.0</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:</td>
<td>64.0</td>
<td>66.0</td>
<td>67.0</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td>69.0</td>
<td>72.0</td>
<td>70.0</td>
</tr>
<tr>
<td>Thyroid</td>
<td>74.0</td>
<td>76.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>56.0</td>
<td>58.0</td>
<td>60.0</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>73.0</td>
<td>76.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>60.0</td>
<td>64.0</td>
<td>63.0</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>74.0</td>
<td>76.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Myeloma</td>
<td>74.0</td>
<td>75.0</td>
<td>77.0</td>
</tr>
<tr>
<td>Leukemia:</td>
<td>74.0</td>
<td>75.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>75.0</td>
<td>78.0</td>
<td>76.0</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>47.0</td>
<td>52.0</td>
<td>48.0</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>78.0</td>
<td>81.0</td>
<td>78.0</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>77.0</td>
<td>80.0</td>
<td>78.0</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>72.0</td>
<td>72.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>71.0</td>
<td>72.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>70.0</td>
<td>72.0</td>
<td>72.0</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>75.0</td>
<td>76.0</td>
<td>75.0</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>76.0</td>
<td>78.0</td>
<td>77.0</td>
</tr>
<tr>
<td>Other:</td>
<td>76.0</td>
<td>78.0</td>
<td>76.0</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>74.0</td>
<td>76.0</td>
<td>74.0</td>
</tr>
</tbody>
</table>

* NCHS public use data file for the total US.
- Statistic could not be calculated. Less than 25 deaths occurred during the time interval.
Table I-14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site, Race and Sex

<table>
<thead>
<tr>
<th>Site</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
<td>Females</td>
<td>Males</td>
</tr>
<tr>
<td></td>
<td>13 SEER Areas, 2000-2002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>45.67</td>
<td>38.09</td>
<td>46.11</td>
</tr>
<tr>
<td></td>
<td>46.91</td>
<td>41.44</td>
<td>47.48</td>
</tr>
<tr>
<td>Invasive and In Situ</td>
<td>1.38</td>
<td>0.68</td>
<td>1.40</td>
</tr>
<tr>
<td>Oral cavity and Pharynx</td>
<td>0.76</td>
<td>0.25</td>
<td>0.78</td>
</tr>
<tr>
<td>Esophagus</td>
<td>1.22</td>
<td>0.75</td>
<td>1.06</td>
</tr>
<tr>
<td>Stomach</td>
<td>5.84</td>
<td>5.51</td>
<td>5.84</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>6.13</td>
<td>5.74</td>
<td>6.13</td>
</tr>
<tr>
<td>Liver and Intrahepatic bile duct</td>
<td>0.89</td>
<td>0.43</td>
<td>0.71</td>
</tr>
<tr>
<td>Pancreas</td>
<td>1.26</td>
<td>1.27</td>
<td>1.28</td>
</tr>
<tr>
<td>Larynx</td>
<td>0.62</td>
<td>0.14</td>
<td>0.62</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>7.58</td>
<td>5.72</td>
<td>7.59</td>
</tr>
<tr>
<td>Melanoma of skin</td>
<td>1.94</td>
<td>1.30</td>
<td>2.33</td>
</tr>
<tr>
<td>Invasive and In Situ</td>
<td>3.13</td>
<td>2.14</td>
<td>3.73</td>
</tr>
<tr>
<td>Breast</td>
<td>0.12</td>
<td>13.22</td>
<td>0.12</td>
</tr>
<tr>
<td>Invasive and In Situ</td>
<td>0.13</td>
<td>15.81</td>
<td>0.14</td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>-</td>
<td>0.74</td>
<td>-</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>-</td>
<td>2.61</td>
<td>-</td>
</tr>
<tr>
<td>Invasive and In Situ</td>
<td>-</td>
<td>2.64</td>
<td>-</td>
</tr>
<tr>
<td>Ovary</td>
<td>-</td>
<td>1.48</td>
<td>-</td>
</tr>
<tr>
<td>Prostate</td>
<td>17.93</td>
<td>-</td>
<td>17.73</td>
</tr>
<tr>
<td>Testis</td>
<td>0.36</td>
<td>-</td>
<td>0.43</td>
</tr>
<tr>
<td>Urinary bladder(Invasive and In Situ)</td>
<td>3.58</td>
<td>1.14</td>
<td>3.99</td>
</tr>
<tr>
<td>Kidney and Renal pelvis</td>
<td>1.56</td>
<td>0.91</td>
<td>1.64</td>
</tr>
<tr>
<td>Brain and Other nervous system</td>
<td>0.65</td>
<td>0.50</td>
<td>0.74</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.35</td>
<td>0.97</td>
<td>0.38</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>0.24</td>
<td>0.19</td>
<td>0.25</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>2.18</td>
<td>1.82</td>
<td>2.32</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>0.70</td>
<td>0.55</td>
<td>0.68</td>
</tr>
<tr>
<td>Leukemia</td>
<td>1.50</td>
<td>1.07</td>
<td>1.61</td>
</tr>
<tr>
<td>Acute Lymphocytic Leukemia</td>
<td>0.12</td>
<td>0.11</td>
<td>0.14</td>
</tr>
<tr>
<td>Chronic Lymphocytic Leukemia</td>
<td>0.53</td>
<td>0.33</td>
<td>0.59</td>
</tr>
<tr>
<td>Acute Myeloid Leukemia</td>
<td>0.46</td>
<td>0.35</td>
<td>0.48</td>
</tr>
<tr>
<td>Chronic Myeloid Leukemia</td>
<td>0.19</td>
<td>0.14</td>
<td>0.19</td>
</tr>
<tr>
<td>Kaposi Sarcoma</td>
<td>0.12</td>
<td>0.02</td>
<td>0.10</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>0.19</td>
<td>0.05</td>
<td>0.22</td>
</tr>
</tbody>
</table>

Note: Invasive cancer only unless specified otherwise.
Table I-15

Lifetime Risk (Percent) of Dying from Cancer by Site, Race and Sex

Total U.S., 2000-2002

<table>
<thead>
<tr>
<th>Site</th>
<th>All Races</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
<td>Females</td>
<td>Males</td>
<td>Females</td>
<td>Males</td>
<td>Females</td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>23.56</td>
<td>19.93</td>
<td>23.62</td>
<td>20.16</td>
<td>24.21</td>
<td>19.43</td>
<td></td>
</tr>
<tr>
<td>Oral cavity and Pharynx</td>
<td>0.38</td>
<td>0.19</td>
<td>0.37</td>
<td>0.19</td>
<td>0.50</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>0.74</td>
<td>0.22</td>
<td>0.74</td>
<td>0.21</td>
<td>0.81</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>0.59</td>
<td>0.40</td>
<td>0.53</td>
<td>0.35</td>
<td>0.89</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>2.36</td>
<td>2.23</td>
<td>2.36</td>
<td>2.20</td>
<td>2.46</td>
<td>2.51</td>
<td></td>
</tr>
<tr>
<td>Liver and Intrahepatic bile duct</td>
<td>0.65</td>
<td>0.37</td>
<td>0.61</td>
<td>0.35</td>
<td>0.69</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>1.17</td>
<td>1.17</td>
<td>1.18</td>
<td>1.16</td>
<td>1.13</td>
<td>1.33</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td>0.23</td>
<td>0.06</td>
<td>0.22</td>
<td>0.06</td>
<td>0.38</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>7.25</td>
<td>4.92</td>
<td>7.33</td>
<td>5.12</td>
<td>7.29</td>
<td>3.97</td>
<td></td>
</tr>
<tr>
<td>Melanoma of skin</td>
<td>0.35</td>
<td>0.20</td>
<td>0.40</td>
<td>0.22</td>
<td>0.03</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>0.03</td>
<td>2.96</td>
<td>0.03</td>
<td>2.96</td>
<td>0.05</td>
<td>3.25</td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>-</td>
<td>0.26</td>
<td>-</td>
<td>0.23</td>
<td>-</td>
<td>0.46</td>
<td></td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>-</td>
<td>0.51</td>
<td>-</td>
<td>0.48</td>
<td>-</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td>-</td>
<td>1.05</td>
<td>-</td>
<td>1.10</td>
<td>-</td>
<td>0.74</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>2.97</td>
<td>-</td>
<td>2.78</td>
<td>-</td>
<td>4.71</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>0.02</td>
<td>-</td>
<td>0.02</td>
<td>-</td>
<td>0.01</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>0.75</td>
<td>0.32</td>
<td>0.80</td>
<td>0.32</td>
<td>0.39</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal pelvis</td>
<td>0.59</td>
<td>0.34</td>
<td>0.61</td>
<td>0.35</td>
<td>0.45</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td>Brain and Other nervous system</td>
<td>0.49</td>
<td>0.39</td>
<td>0.53</td>
<td>0.42</td>
<td>0.23</td>
<td>0.21</td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.04</td>
<td>0.06</td>
<td>0.05</td>
<td>0.06</td>
<td>0.03</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>0.05</td>
<td>0.04</td>
<td>0.05</td>
<td>0.04</td>
<td>0.04</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>0.94</td>
<td>0.81</td>
<td>1.00</td>
<td>0.86</td>
<td>0.50</td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>0.46</td>
<td>0.40</td>
<td>0.44</td>
<td>0.38</td>
<td>0.63</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>0.97</td>
<td>0.72</td>
<td>1.02</td>
<td>0.75</td>
<td>0.64</td>
<td>0.54</td>
<td></td>
</tr>
<tr>
<td>Acute Lymphocytic Leukemia</td>
<td>0.05</td>
<td>0.04</td>
<td>0.05</td>
<td>0.04</td>
<td>0.03</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Chronic Lymphocytic Leukemia</td>
<td>0.23</td>
<td>0.15</td>
<td>0.24</td>
<td>0.16</td>
<td>0.16</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>Acute Myeloid Leukemia</td>
<td>0.33</td>
<td>0.25</td>
<td>0.35</td>
<td>0.26</td>
<td>0.19</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Chronic Myeloid Leukemia</td>
<td>0.07</td>
<td>0.05</td>
<td>0.07</td>
<td>0.05</td>
<td>0.06</td>
<td>0.05</td>
<td></td>
</tr>
</tbody>
</table>
## Table I-16

**US AND SEER DEATH RATES BY PRIMARY CANCER SITE AND RACE/ETHNICITY, 1992-2002**

<table>
<thead>
<tr>
<th>Site</th>
<th>Total United States</th>
<th>SEER 11 Areas, Alaska and Rural Georgia</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>258.6</td>
<td>252.5</td>
</tr>
<tr>
<td>Female</td>
<td>169.2</td>
<td>167.9</td>
</tr>
<tr>
<td>Oral Cavity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>3.0</td>
<td>2.8</td>
</tr>
<tr>
<td>Female</td>
<td>1.7</td>
<td>1.7</td>
</tr>
<tr>
<td>&amp; Pharynx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>4.5</td>
<td>4.2</td>
</tr>
<tr>
<td>Female</td>
<td>1.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Esophagus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7.6</td>
<td>7.2</td>
</tr>
<tr>
<td>Female</td>
<td>1.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Stomach</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>4.9</td>
<td>4.4</td>
</tr>
<tr>
<td>Female</td>
<td>3.4</td>
<td>3.0</td>
</tr>
<tr>
<td>Colon &amp; Rectum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>26.3</td>
<td>25.8</td>
</tr>
<tr>
<td>Female</td>
<td>18.3</td>
<td>17.8</td>
</tr>
<tr>
<td>Liver &amp; Intrahepatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>4.4</td>
<td>4.1</td>
</tr>
<tr>
<td>Female</td>
<td>6.5</td>
<td>5.9</td>
</tr>
<tr>
<td>Pancreas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>10.6</td>
<td>10.3</td>
</tr>
<tr>
<td>Female</td>
<td>12.3</td>
<td>12.0</td>
</tr>
<tr>
<td>Larynx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.5</td>
<td>1.3</td>
</tr>
<tr>
<td>Female</td>
<td>2.7</td>
<td>2.4</td>
</tr>
<tr>
<td>Lung &amp; Bronchus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>40.3</td>
<td>41.1</td>
</tr>
<tr>
<td>Female</td>
<td>57.1</td>
<td>56.9</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>3.9</td>
<td>4.4</td>
</tr>
<tr>
<td>Female</td>
<td>1.8</td>
<td>2.0</td>
</tr>
<tr>
<td>Breast</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>28.5</td>
<td>28.0</td>
</tr>
</tbody>
</table>

---

[^a]: NCCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
[^b]: American Indian/Alaskan Native.
[^c]: Asian/Pacific Islander.
[^d]: Mortality data for Hispanics (Hisp) and White Non-Hispanics (W-NHisp) do not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
[^e]: Statistic could not be calculated.
Table I-16 - continued
US AND SEER DEATH RATES BY PRIMARY CANCER SITE AND RACE/ETHNICITY, 1992-2002

<table>
<thead>
<tr>
<th>Site</th>
<th>Total United Statesa</th>
<th>SEER 11 Areas, Alaska and Rural Georgiaa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>White</td>
<td>Black</td>
</tr>
<tr>
<td>Cervix Female</td>
<td>3.0</td>
<td>2.7</td>
</tr>
<tr>
<td>Corpus &amp; Uterus, NOS Female</td>
<td>4.1</td>
<td>3.9</td>
</tr>
<tr>
<td>Ovary Female</td>
<td>9.0</td>
<td>9.3</td>
</tr>
<tr>
<td>Prostate Male</td>
<td>33.9</td>
<td>31.2</td>
</tr>
<tr>
<td>Testis Male</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Urinary Both Sexes</td>
<td>4.4</td>
<td>4.5</td>
</tr>
<tr>
<td>Bladder Male</td>
<td>7.7</td>
<td>8.0</td>
</tr>
<tr>
<td>Kidney &amp; Pelvis Both Sexes</td>
<td>4.2</td>
<td>4.3</td>
</tr>
<tr>
<td>Renal Male</td>
<td>6.2</td>
<td>6.2</td>
</tr>
<tr>
<td>Nervous System Female</td>
<td>5.7</td>
<td>6.1</td>
</tr>
<tr>
<td>Thyroid Both Sexes</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Hodgkin Both Sexes</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Lymphoma Male</td>
<td>0.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma Both Sexes</td>
<td>8.4</td>
<td>8.7</td>
</tr>
<tr>
<td>Myeloma Both Sexes</td>
<td>3.9</td>
<td>3.6</td>
</tr>
<tr>
<td>Leukemia Both Sexes</td>
<td>7.7</td>
<td>7.9</td>
</tr>
</tbody>
</table>

* NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
  b American Indian/Alaskan Native.
  c Asian/Pacific Islander.
  d Mortality data for Hispanics (Hisp) and White Non-Hispanics (W-NHispd) do not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
  e Statistic could not be calculated.

(b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 27 years (1975-2001); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1997-2001).

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 27-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 27-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 27-year limited duration prevalence.

In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.

### Table I-17

**US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2002**

**USING DIFFERENT TUMOR INCLUSION CRITERIA**

<table>
<thead>
<tr>
<th>Site/Sex</th>
<th>5-Year Limited Duration</th>
<th>27-year Limited Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Invasive Tumor Ever</td>
<td>Invasive Tumor Ever</td>
</tr>
<tr>
<td>All Sites</td>
<td>3,867,003</td>
<td>3,941,332</td>
</tr>
<tr>
<td>Male</td>
<td>1,957,153</td>
<td>1,983,555</td>
</tr>
<tr>
<td>Female</td>
<td>1,909,850</td>
<td>1,957,777</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx</td>
<td>82,465</td>
<td>93,657</td>
</tr>
<tr>
<td>Male</td>
<td>54,587</td>
<td>61,351</td>
</tr>
<tr>
<td>Female</td>
<td>27,878</td>
<td>32,306</td>
</tr>
<tr>
<td>Esophagus</td>
<td>16,212</td>
<td>19,256</td>
</tr>
<tr>
<td>Male</td>
<td>12,545</td>
<td>14,664</td>
</tr>
<tr>
<td>Female</td>
<td>3,667</td>
<td>4,592</td>
</tr>
<tr>
<td>Stomach</td>
<td>29,294</td>
<td>33,978</td>
</tr>
<tr>
<td>Male</td>
<td>17,931</td>
<td>20,805</td>
</tr>
<tr>
<td>Female</td>
<td>11,363</td>
<td>13,173</td>
</tr>
<tr>
<td>Colon &amp; Rectum</td>
<td>409,449</td>
<td>468,805</td>
</tr>
<tr>
<td>Male</td>
<td>205,302</td>
<td>235,516</td>
</tr>
<tr>
<td>Female</td>
<td>204,147</td>
<td>233,289</td>
</tr>
<tr>
<td>Liver &amp; Intrahep</td>
<td>11,552</td>
<td>13,206</td>
</tr>
<tr>
<td>Male</td>
<td>7,508</td>
<td>8,594</td>
</tr>
<tr>
<td>Female</td>
<td>4,044</td>
<td>4,612</td>
</tr>
<tr>
<td>Pancreas</td>
<td>19,344</td>
<td>22,700</td>
</tr>
<tr>
<td>Male</td>
<td>9,438</td>
<td>11,214</td>
</tr>
<tr>
<td>Female</td>
<td>9,906</td>
<td>11,486</td>
</tr>
<tr>
<td>Larynx</td>
<td>32,997</td>
<td>37,965</td>
</tr>
<tr>
<td>Male</td>
<td>26,181</td>
<td>30,101</td>
</tr>
<tr>
<td>Female</td>
<td>6,816</td>
<td>7,864</td>
</tr>
<tr>
<td>Lung &amp; Bronchus</td>
<td>202,674</td>
<td>246,254</td>
</tr>
<tr>
<td>Male</td>
<td>100,886</td>
<td>123,709</td>
</tr>
<tr>
<td>Female</td>
<td>101,788</td>
<td>122,545</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>202,999</td>
<td>223,960</td>
</tr>
<tr>
<td>Male</td>
<td>107,851</td>
<td>120,689</td>
</tr>
<tr>
<td>Female</td>
<td>95,148</td>
<td>103,281</td>
</tr>
<tr>
<td>Breast</td>
<td>810,067</td>
<td>867,306</td>
</tr>
<tr>
<td>Female</td>
<td>44,613</td>
<td>46,898</td>
</tr>
<tr>
<td>Cervix</td>
<td>142,978</td>
<td>160,405</td>
</tr>
<tr>
<td>Corpus &amp; Uterus</td>
<td>54,659</td>
<td>62,758</td>
</tr>
</tbody>
</table>
In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. In method (d) the 1981 melanoma is counted for the melanoma and all sites 27-year limited duration prevalence. In method (c) the melanoma is the woman’s first cancer, and is counted for the melanoma and all sites diagnosed during the previous 27 years (1975-2001); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1997-2001).

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman’s first cancer, and is counted for the melanoma and all sites 27-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 27-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 27-year limited duration prevalence.

In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.

---

### Table I-17 - continued

#### US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2002

**US 2002 cancer prevalence counts are based on 2002 cancer prevalence proportions from the SEER 9 registries and 1/1/2002 US population estimates based on the average of 2001 and 2002 population estimates from the US Bureau of the Census.**

#### USING DIFFERENT TUMOR INCLUSION CRITERIA

| Site/sex | 5-Year Limited Duration | | 27-Year Limited Duration | |
|---|---| |---|---|
| | 1st | 1st Per Site | In Previous | In Previous |
| | Tumor Ever<sup>c</sup> | in Previous 27 Years<sup>d</sup> | 5 Years<sup>a</sup> | Tumor Ever<sup>c</sup> | 27 Years<sup>d</sup> |
| Prostate | Male | 892,138 | 960,511 | 960,545 | 1,826,301 | 1,949,727 |
| | Male | 37,578 | 38,062 | 38,571 | 144,174 | 145,865 |
| Urinary Bladder | Male | 184,483 | 221,675 | 223,454 | 471,823 | 535,752 |
| | Male | 138,422 | 166,292 | 167,816 | 349,628 | 395,599 |
| Kidney & Renal Pelvis | Male | 89,323 | 107,038 | 107,849 | 207,723 | 237,885 |
| | Male | 53,720 | 65,276 | 65,792 | 123,059 | 141,698 |
| | Female | 35,603 | 41,762 | 42,057 | 84,664 | 96,187 |
| Brain & Nervous System | Male | 35,503 | 37,509 | 37,641 | 91,881 | 94,763 |
| | Male | 19,416 | 20,452 | 20,517 | 49,872 | 51,377 |
| | Female | 16,087 | 17,057 | 17,124 | 42,009 | 43,386 |
| Thyroid | Male | 88,240 | 94,590 | 94,806 | 279,685 | 292,893 |
| | Male | 20,450 | 22,504 | 22,553 | 63,721 | 67,300 |
| | Female | 67,790 | 72,086 | 72,253 | 215,964 | 225,593 |
| Hodgkin Lymphoma | Male | 33,241 | 34,605 | 34,627 | 125,113 | 127,804 |
| | Male | 17,560 | 18,312 | 18,312 | 65,330 | 66,779 |
| | Female | 15,681 | 16,293 | 16,315 | 59,783 | 61,025 |
| Non-Hodgkin Lymphoma | Male | 154,821 | 175,583 | 176,195 | 332,657 | 365,300 |
| | Male | 81,328 | 92,287 | 92,613 | 172,701 | 188,781 |
| | Female | 73,493 | 83,296 | 83,582 | 159,956 | 176,519 |
| Myeloma | Male | 34,833 | 39,821 | 39,844 | 49,931 | 56,104 |
| | Male | 18,832 | 21,683 | 21,706 | 27,208 | 30,707 |
| | Female | 16,001 | 18,138 | 18,138 | 22,723 | 25,397 |
| Leukemia | Male | 80,095 | 89,786 | 89,845 | 183,579 | 198,257 |
| | Male | 46,350 | 52,154 | 52,201 | 103,787 | 112,084 |
| | Female | 33,745 | 37,632 | 37,644 | 79,792 | 86,173 |
| Acute Lymphocytic Leuk | Male | 13,598 | 13,731 | 13,731 | 44,730 | 44,955 |
| | Male | 7,581 | 7,624 | 7,624 | 24,523 | 24,604 |
| | Female | 6,017 | 6,107 | 6,107 | 20,207 | 20,351 |
| Childhood (0-19) | Male | 55,930 | 56,015 | 56,307 | 215,915 | 216,360 |
| | Male | 29,328 | 29,380 | 29,523 | 110,475 | 110,683 |
| | Female | 26,602 | 26,635 | 26,784 | 105,440 | 105,677 |
| Kaposi's Sarcoma | Male | 7,140 | 7,674 | 7,708 | 19,711 | 20,644 |
| | Male | 6,545 | 7,024 | 7,058 | 18,332 | 19,151 |
| | Female | 595 | 650 | 650 | 1,379 | 1,493 |
| Mesoethelioma | Male | 3,065 | 3,626 | 3,626 | 4,422 | 5,077 |
| | Male | 2,144 | 2,643 | 2,643 | 2,686 | 3,256 |
| | Female | 921 | 983 | 983 | 1,736 | 1,821 |
Cases diagnosed more than 27 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Cases diagnosed more than 27 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

---

### Table I-18

**US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2002**

<table>
<thead>
<tr>
<th>Site/Sex</th>
<th>All Ages</th>
<th>Age Specific</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0-9</td>
</tr>
<tr>
<td><strong>All Sites</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>4,503,895</td>
<td>16,687</td>
</tr>
<tr>
<td>Females</td>
<td>5,642,429</td>
<td>14,040</td>
</tr>
<tr>
<td><strong>Breast</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>11,780</td>
<td>0</td>
</tr>
<tr>
<td>Females</td>
<td>2,278,269</td>
<td>0</td>
</tr>
<tr>
<td><strong>Colon &amp; Rectum</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>505,267</td>
<td>0</td>
</tr>
<tr>
<td>Females</td>
<td>546,415</td>
<td>11</td>
</tr>
<tr>
<td><strong>Corpus &amp; Uterus, NOS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>571,854</td>
<td>0</td>
</tr>
<tr>
<td><strong>Esophagus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>17,651</td>
<td>0</td>
</tr>
<tr>
<td>Females</td>
<td>5,751</td>
<td>0</td>
</tr>
<tr>
<td><strong>Larynx</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>78,348</td>
<td>0</td>
</tr>
<tr>
<td>Females</td>
<td>19,555</td>
<td>0</td>
</tr>
<tr>
<td><strong>Lung &amp; Bronchus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>174,384</td>
<td>34</td>
</tr>
<tr>
<td>Females</td>
<td>176,295</td>
<td>11</td>
</tr>
<tr>
<td><strong>Melanoma of the Skin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>304,097</td>
<td>78</td>
</tr>
<tr>
<td>Females</td>
<td>325,725</td>
<td>57</td>
</tr>
<tr>
<td><strong>Non-Hodgkin Lymphoma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>180,337</td>
<td>614</td>
</tr>
<tr>
<td>Females</td>
<td>166,702</td>
<td>307</td>
</tr>
<tr>
<td><strong>Oral Cavity &amp; Pharynx</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>147,272</td>
<td>56</td>
</tr>
<tr>
<td>Females</td>
<td>84,527</td>
<td>96</td>
</tr>
<tr>
<td><strong>Ovary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>169,875</td>
<td>56</td>
</tr>
<tr>
<td><strong>Prostate</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>1,831,929</td>
<td>34</td>
</tr>
<tr>
<td>Females</td>
<td>25,053</td>
<td>11</td>
</tr>
<tr>
<td><strong>Urinary Bladder</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>367,550</td>
<td>28</td>
</tr>
<tr>
<td>Females</td>
<td>131,649</td>
<td>22</td>
</tr>
<tr>
<td><strong>Myeloma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>27,357</td>
<td>0</td>
</tr>
<tr>
<td>Females</td>
<td>23,127</td>
<td>0</td>
</tr>
</tbody>
</table>

---

*a* US 2002 cancer prevalence counts are based on 2002 cancer prevalence proportions from the SEER 9 registries and 1/1/2002 US population estimates based on the average of 2001 and 2002 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

*b* Cases diagnosed more than 27 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

*c* Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.
### Table I-19

**AGE-ADJUSTED RATES AND TRENDS** *FOR THE TOP 15 CANCER SITES* *BY RACE/ETHNICITY*

#### SEER Cancer Incidence* 1992-2002

<table>
<thead>
<tr>
<th>Race</th>
<th>All Sites</th>
<th>Rate</th>
<th>APC</th>
<th>All Sites</th>
<th>Rate</th>
<th>APC</th>
<th>All Sites</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Both Sexes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All Races</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>475.4</td>
<td>-0.6</td>
<td></td>
<td>All Sites</td>
<td>483.5</td>
<td>-0.4</td>
<td>All Sites</td>
<td>526.7</td>
<td>-1.0</td>
</tr>
<tr>
<td>Prostate</td>
<td>180.1</td>
<td>-2.0</td>
<td></td>
<td>Prostate</td>
<td>175.5</td>
<td>-2.1</td>
<td>Prostate</td>
<td>283.8</td>
<td>-1.9</td>
</tr>
<tr>
<td>Breast (Females)</td>
<td>132.4</td>
<td>0.4</td>
<td></td>
<td>Breast (Females)</td>
<td>138.3</td>
<td>0.5</td>
<td>Breast (Females)</td>
<td>120.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>63.2</td>
<td>-1.3</td>
<td></td>
<td>Lung and Bronchus</td>
<td>63.7</td>
<td>-1.1</td>
<td>Lung and Bronchus</td>
<td>81.6</td>
<td>-1.4</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>53.9</td>
<td>-0.8</td>
<td></td>
<td>Colon and Rectum</td>
<td>53.6</td>
<td>-0.9</td>
<td>Colon and Rectum</td>
<td>62.6</td>
<td>-0.3</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>24.4</td>
<td>-0.2</td>
<td></td>
<td>Corpus and Uterus, NOS</td>
<td>25.9</td>
<td>-0.3</td>
<td>Corpus and Uterus, NOS</td>
<td>18.4</td>
<td>1.8</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>20.3</td>
<td>-0.2</td>
<td></td>
<td>Urinary Bladder</td>
<td>22.3</td>
<td>0.0</td>
<td>Urinary Bladder</td>
<td>16.0</td>
<td>-1.9</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>19.2</td>
<td>0.1</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
<td>20.2</td>
<td>0.1</td>
<td>Non-Hodgkin Lymphoma</td>
<td>14.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>16.2</td>
<td>2.4</td>
<td></td>
<td>Melanoma of the Skin</td>
<td>19.2</td>
<td>2.9</td>
<td>Melanoma of the Skin</td>
<td>13.7</td>
<td>-1.5</td>
</tr>
<tr>
<td>Ovary</td>
<td>14.2</td>
<td>-0.9</td>
<td></td>
<td>Ovary</td>
<td>15.1</td>
<td>-0.8</td>
<td>Ovary</td>
<td>13.1</td>
<td>2.3</td>
</tr>
<tr>
<td>Leukemia</td>
<td>12.5</td>
<td>-0.9</td>
<td></td>
<td>Leukemia</td>
<td>13.2</td>
<td>-0.8</td>
<td>Leukemia</td>
<td>12.6</td>
<td>-2.8</td>
</tr>
<tr>
<td>Pancreas</td>
<td>11.1</td>
<td>-0.3</td>
<td></td>
<td>Pancreas</td>
<td>11.4</td>
<td>1.7</td>
<td>Pancreas</td>
<td>12.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>11.1</td>
<td>1.5</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
<td>11.0</td>
<td>-1.2</td>
<td>Kidney and Renal Pelvis</td>
<td>11.5</td>
<td>-1.3</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>11.0</td>
<td>-1.5</td>
<td></td>
<td>Oral Cavity and Pharynx</td>
<td>10.9</td>
<td>0.0</td>
<td>Oral Cavity and Pharynx</td>
<td>10.3</td>
<td>-1.6</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>9.7</td>
<td>-2.8</td>
<td></td>
<td>Cervix Uteri</td>
<td>9.3</td>
<td>-2.2</td>
<td>Cervix Uteri</td>
<td>10.0</td>
<td>-1.4</td>
</tr>
<tr>
<td>Stomach</td>
<td>9.1</td>
<td>-1.5</td>
<td></td>
<td>Stomach</td>
<td>7.8</td>
<td>-1.6</td>
<td>Stomach</td>
<td>10.5</td>
<td>-1.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Asian/Pacific Islander</th>
<th>Rate</th>
<th>APC</th>
<th>American Indian/Alaska Native</th>
<th>Rate</th>
<th>APC</th>
<th>Hispanic</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>339.7</td>
<td>-0.6</td>
<td>All Sites</td>
<td>251.9</td>
<td>-2.7</td>
<td>All Sites</td>
<td>354.6</td>
<td>-0.4</td>
</tr>
<tr>
<td>Prostate</td>
<td>104.6</td>
<td>-1.7</td>
<td>Prostate</td>
<td>63.4</td>
<td>-6.8</td>
<td>Prostate</td>
<td>143.1</td>
<td>-0.7</td>
</tr>
<tr>
<td>Breast (Females)</td>
<td>92.8</td>
<td>1.5</td>
<td>Breast (Females)</td>
<td>60.7</td>
<td>-3.5</td>
<td>Breast (Females)</td>
<td>88.2</td>
<td>0.6</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>47.0</td>
<td>-0.3</td>
<td>Lung and Bronchus</td>
<td>36.3</td>
<td>-4.2</td>
<td>Lung and Bronchus</td>
<td>38.9</td>
<td>0.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>17.4</td>
<td>-3.3</td>
<td>Stomach</td>
<td>10.8</td>
<td>2.6</td>
<td>Stomach</td>
<td>16.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>17.0</td>
<td>1.6</td>
<td>Colon and Rectum</td>
<td>10.8</td>
<td>2.6</td>
<td>Colon and Rectum</td>
<td>16.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>13.8</td>
<td>0.6</td>
<td>Liver and IBD</td>
<td>10.1</td>
<td>-1</td>
<td>Liver and IBD</td>
<td>13.5</td>
<td>-1.7</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>13.7</td>
<td>0.6</td>
<td>Non-Hodgkin Lymphoma</td>
<td>8.9</td>
<td>-4</td>
<td>Non-Hodgkin Lymphoma</td>
<td>11.9</td>
<td>-0.2</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>10.5</td>
<td>-4.9</td>
<td>Cervix Uteri</td>
<td>7.5</td>
<td>-1</td>
<td>Cervix Uteri</td>
<td>10.8</td>
<td>-0.1</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.4</td>
<td>0.3</td>
<td>Pancreas</td>
<td>7.5</td>
<td>-1</td>
<td>Pancreas</td>
<td>10.8</td>
<td>2.4</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>9.7</td>
<td>0.1</td>
<td>Urinary Bladder</td>
<td>7.2</td>
<td>-6.7</td>
<td>Urinary Bladder</td>
<td>10.0</td>
<td>-0.2</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>9.3</td>
<td>-0.5</td>
<td>Oral Cavity and Pharynx</td>
<td>6.6</td>
<td>-6.9</td>
<td>Oral Cavity and Pharynx</td>
<td>9.5</td>
<td>0.7</td>
</tr>
<tr>
<td>Thyroid</td>
<td>8.9</td>
<td>1.3</td>
<td>Thyroid</td>
<td>6.6</td>
<td>2.4</td>
<td>Thyroid</td>
<td>8.9</td>
<td>3.4</td>
</tr>
<tr>
<td>Leukemia</td>
<td>7.8</td>
<td>-1.3</td>
<td>Leukemia</td>
<td>4.9</td>
<td>2.4</td>
<td>Leukemia</td>
<td>6.7</td>
<td>-2.1</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.


Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Incidence data for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

Incidence data for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

The APC is significantly different from zero (p<.05).

IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.


* Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

* Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

* Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

* Incidence data for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

* The APC is significantly different from zero (p<.05).

* IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>All Races Rate</th>
<th>All Races APC</th>
<th>White Rate</th>
<th>White APC</th>
<th>Black Rate</th>
<th>Black APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>570.9</td>
<td>-1.3*</td>
<td>572.7</td>
<td>-1.3*</td>
<td>716.6</td>
<td>-1.7*</td>
</tr>
<tr>
<td>Prostate</td>
<td>180.1</td>
<td>-2.0*</td>
<td>178.5</td>
<td>-2.1*</td>
<td>263.8</td>
<td>-1.9*</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>82.7</td>
<td>-2.2*</td>
<td>81.5</td>
<td>-2.1*</td>
<td>122.8</td>
<td>-2.5*</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>64.0</td>
<td>-1.2*</td>
<td>63.8</td>
<td>-1.3*</td>
<td>72.9</td>
<td>-0.5*</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>36.1</td>
<td>-0.2</td>
<td>38.7</td>
<td>-0.1*</td>
<td>20.7</td>
<td>-3.1*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>23.7</td>
<td>-0.5</td>
<td>24.9</td>
<td>-0.4*</td>
<td>20.2</td>
<td>-0.2*</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>20.4</td>
<td>2.5*</td>
<td>24.0</td>
<td>2.9*</td>
<td>26.9</td>
<td>2.3*</td>
</tr>
<tr>
<td>Leukemia</td>
<td>16.4</td>
<td>-1.1*</td>
<td>17.4</td>
<td>-1.1*</td>
<td>19.5</td>
<td>-2.8*</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>16.4</td>
<td>-1.8*</td>
<td>16.2</td>
<td>-1.5*</td>
<td>18.5</td>
<td>2.2*</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>15.5</td>
<td>1.4*</td>
<td>15.9</td>
<td>1.6*</td>
<td>17.5</td>
<td>-2.5*</td>
</tr>
<tr>
<td>Stomach</td>
<td>13.1</td>
<td>-2.1*</td>
<td>12.5</td>
<td>0.1*</td>
<td>13.5</td>
<td>-0.7*</td>
</tr>
<tr>
<td>Pancreas</td>
<td>12.7</td>
<td>-0.4*</td>
<td>11.3</td>
<td>-2.1*</td>
<td>12.9</td>
<td>-1.6</td>
</tr>
<tr>
<td>Liver &amp; IBDf</td>
<td>8.6</td>
<td>3.0*</td>
<td>8.5</td>
<td>-0.4*</td>
<td>12.4</td>
<td>5.7*</td>
</tr>
<tr>
<td>Brain and ONSf</td>
<td>7.7</td>
<td>0.7</td>
<td>7.4</td>
<td>1.5*</td>
<td>12.4</td>
<td>5.7*</td>
</tr>
<tr>
<td>Esophagus</td>
<td>7.6</td>
<td>0.3</td>
<td>7.1</td>
<td>-3.3*</td>
<td>10.8</td>
<td>4.5*</td>
</tr>
<tr>
<td>Larynx</td>
<td>7.2</td>
<td>-3.3*</td>
<td>6.8</td>
<td>2.9*</td>
<td>6.4</td>
<td>-12.7*</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

All Races statistics not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.


Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Incidence data for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

Incidence data for Hispanics is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

The APC is significantly different from zero (p<.05).

IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
Table I-21
AGE-ADJUSTED RATES AND TRENDS* FOR THE TOP 15 CANCER SITES** BY RACE/ETHNICITY

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th>Rate</th>
<th>APC</th>
<th>White</th>
<th>Rate</th>
<th>APC</th>
<th>Black</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>412.1</td>
<td>0.1</td>
<td></td>
<td>All Sites</td>
<td>425.7</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>132.4</td>
<td>0.4</td>
<td></td>
<td>Breast</td>
<td>138.3</td>
<td>0.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>49.2</td>
<td>-0.2</td>
<td></td>
<td>Lung and Bronchus</td>
<td>51.3</td>
<td>-0.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>46.4</td>
<td>-0.6</td>
<td></td>
<td>Colon and Rectum</td>
<td>45.9</td>
<td>-0.7*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>24.4</td>
<td>-0.2</td>
<td></td>
<td>Corpus and Uterus, NOS</td>
<td>25.9</td>
<td>-0.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>15.5</td>
<td>0.8*</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
<td>16.3</td>
<td>0.8*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td>14.2</td>
<td>-0.9</td>
<td></td>
<td>Ovary</td>
<td>15.1</td>
<td>-0.8*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>13.2</td>
<td>2.3*</td>
<td></td>
<td>Melanoma of the Skin</td>
<td>15.9</td>
<td>3.0*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>9.8</td>
<td>4.8*</td>
<td></td>
<td>Pancreas</td>
<td>10.2</td>
<td>5.2*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>9.7</td>
<td>-2.8</td>
<td></td>
<td>Thyroid</td>
<td>10.1</td>
<td>-0.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>9.6</td>
<td>-0.8</td>
<td></td>
<td>Leukemia</td>
<td>9.9</td>
<td>-0.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>9.2</td>
<td>-0.4</td>
<td></td>
<td>Urinary Bladder</td>
<td>9.6</td>
<td>-0.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>7.6</td>
<td>1.4*</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
<td>7.9</td>
<td>1.5*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>6.7</td>
<td>-1.1</td>
<td></td>
<td>Oral Cavity and Pharynx</td>
<td>6.7</td>
<td>-1.2*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>6.2</td>
<td>-0.7</td>
<td></td>
<td>Stomach</td>
<td>6.0</td>
<td>-0.1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Asian/Pacific Islander</th>
<th>Rate</th>
<th>APC</th>
<th>American Indian/Alaska Native</th>
<th>Rate</th>
<th>APC</th>
<th>Hispanic*</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>301.2</td>
<td>0.3</td>
<td></td>
<td>All Sites</td>
<td>229.8</td>
<td>-1.7*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>92.8</td>
<td>1.5*</td>
<td></td>
<td>Breast</td>
<td>60.7</td>
<td>-3.5*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>39.3</td>
<td>0.0</td>
<td></td>
<td>Colon and Rectum</td>
<td>32.3</td>
<td>-1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>28.4</td>
<td>0.0</td>
<td></td>
<td>Lung and Bronchus</td>
<td>25.8</td>
<td>-2.8*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>17.0</td>
<td>1.6*</td>
<td></td>
<td>Corpus and Uterus, NOS</td>
<td>10.1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>12.9</td>
<td>-2.9*</td>
<td></td>
<td>Stomach</td>
<td>8.9</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>11.7</td>
<td>2.0</td>
<td></td>
<td>Thyroid</td>
<td>7.9</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>11.2</td>
<td>1.2</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
<td>7.9</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>10.5</td>
<td>-4.9*</td>
<td></td>
<td>Cervix Uteri</td>
<td>7.3</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.4</td>
<td>0.3</td>
<td></td>
<td>Pancreas</td>
<td>6.9</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>8.3</td>
<td>2.0*</td>
<td></td>
<td>Cervix Uteri</td>
<td>6.6</td>
<td>-6.9*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; IBD†</td>
<td>7.9</td>
<td>0.2</td>
<td></td>
<td>Liver &amp; IBD†</td>
<td>6.1</td>
<td>2.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>6.2</td>
<td>-2.2*</td>
<td></td>
<td>Leukemia</td>
<td>4.5</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>5.8</td>
<td>-0.1</td>
<td></td>
<td>Oral Cavity and Pharynx</td>
<td>4.0</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>4.2</td>
<td>-1.3</td>
<td></td>
<td>Urinary Bladder</td>
<td>3.9</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>4.1</td>
<td>2.8*</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
<td>3.9</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.
Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.
Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Incidence for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.
The APC is significantly different from zero (p<.05).
IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
Table I-22
AGE-ADJUSTED RATES AND TRENDS* FOR THE TOP 15 CANCER SITES** BY RACE/ETHNICITY

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate</td>
<td>APC</td>
<td>Rate</td>
</tr>
<tr>
<td>All Sites</td>
<td>204.0</td>
<td>-1.0*</td>
<td>200.8</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>57.1</td>
<td>-0.8*</td>
<td>56.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>33.9</td>
<td>-3.6*</td>
<td>31.2</td>
</tr>
<tr>
<td>Breast (Females)</td>
<td>28.5</td>
<td>-2.4*</td>
<td>28.0</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>21.6</td>
<td>-1.8*</td>
<td>21.1</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.6</td>
<td>-0.1</td>
<td>10.3</td>
</tr>
<tr>
<td>Ovary</td>
<td>9.0</td>
<td>-0.5*</td>
<td>9.3</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>8.4</td>
<td>-0.8</td>
<td>8.7</td>
</tr>
<tr>
<td>Leukemia</td>
<td>7.7</td>
<td>-0.6</td>
<td>7.9</td>
</tr>
<tr>
<td>Stomach</td>
<td>4.9</td>
<td>-3.0*</td>
<td>5.0</td>
</tr>
<tr>
<td>Brain and ONS f</td>
<td>4.7</td>
<td>-0.9*</td>
<td>4.5</td>
</tr>
<tr>
<td>Liver &amp; IBD f</td>
<td>4.4</td>
<td>1.9</td>
<td>4.4</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>4.4</td>
<td>-0.3*</td>
<td>4.3</td>
</tr>
<tr>
<td>Esophagus</td>
<td>4.3</td>
<td>0.6</td>
<td>4.1</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>4.2</td>
<td>-0.1</td>
<td>4.1</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>4.1</td>
<td>-0.1</td>
<td>3.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Asian/Pacific Islander</th>
<th>Rate</th>
<th>APC</th>
<th>Rate</th>
<th>APC</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>125.1</td>
<td>-1.7*</td>
<td>135.3</td>
<td>-0.7</td>
<td>137.4</td>
<td>-0.6*</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>28.6</td>
<td>-1.5</td>
<td>36.3</td>
<td>-0.9*</td>
<td>25.5</td>
<td>-0.9*</td>
</tr>
<tr>
<td>Prostate</td>
<td>14.1</td>
<td>-5.2*</td>
<td>21.5</td>
<td>-4.5*</td>
<td>24.7</td>
<td>-2.4*</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>13.5</td>
<td>-1.9*</td>
<td>14.4</td>
<td>-1.5</td>
<td>17.7</td>
<td>-1.9*</td>
</tr>
<tr>
<td>Breast (Females)</td>
<td>12.9</td>
<td>-0.6</td>
<td>13.8</td>
<td>0.7</td>
<td>14.2</td>
<td>-0.2</td>
</tr>
<tr>
<td>Liver &amp; IBD f</td>
<td>10.8</td>
<td>-0.7</td>
<td>6.2</td>
<td>2.2</td>
<td>8.4</td>
<td>-0.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>9.7</td>
<td>-3.9*</td>
<td>5.5</td>
<td>-1.1</td>
<td>7.4</td>
<td>-1.8*</td>
</tr>
<tr>
<td>Pancreas</td>
<td>7.5</td>
<td>-0.6</td>
<td>5.5</td>
<td>-1.1</td>
<td>7.2</td>
<td>2.0*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>5.2</td>
<td>-1.7*</td>
<td>5.1</td>
<td>-0.4</td>
<td>6.5</td>
<td>0.6</td>
</tr>
<tr>
<td>Ovary</td>
<td>4.8</td>
<td>0.0</td>
<td>4.9</td>
<td>0.6</td>
<td>6.2</td>
<td>-0.6</td>
</tr>
<tr>
<td>Leukemia</td>
<td>4.3</td>
<td>-1.4</td>
<td>4.4</td>
<td>2.1</td>
<td>5.3</td>
<td>-0.1</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>2.9</td>
<td>-3.3*</td>
<td>4.1</td>
<td>-1.8</td>
<td>3.8</td>
<td>-3.0*</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>2.5</td>
<td>-2.4*</td>
<td>3.2</td>
<td>-4.7*</td>
<td>3.8</td>
<td>0.4</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>2.2</td>
<td>1.4</td>
<td>2.9</td>
<td>-0.5</td>
<td>3.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Esophagus</td>
<td>2.1</td>
<td>-3.3*</td>
<td>2.7</td>
<td>2.6*</td>
<td>2.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Brain and ONS f</td>
<td>1.9</td>
<td>0.1</td>
<td>2.6</td>
<td>0.3</td>
<td>2.9</td>
<td>0.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>American Indian/Alaska Native</th>
<th>Rate</th>
<th>APC</th>
<th>Rate</th>
<th>APC</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>135.3</td>
<td>-0.7</td>
<td>17.7</td>
<td>-1.9*</td>
<td>137.4</td>
<td>-0.6*</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>36.3</td>
<td>-0.9*</td>
<td>17.7</td>
<td>-1.9*</td>
<td>25.5</td>
<td>-0.9*</td>
</tr>
<tr>
<td>Prostate</td>
<td>21.5</td>
<td>-4.5*</td>
<td>17.7</td>
<td>-1.9*</td>
<td>24.7</td>
<td>-2.4*</td>
</tr>
<tr>
<td>Breast (Females)</td>
<td>14.4</td>
<td>-1.5</td>
<td>14.2</td>
<td>-0.2</td>
<td>17.7</td>
<td>-1.9*</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>13.8</td>
<td>0.7</td>
<td>8.4</td>
<td>-0.1</td>
<td>7.4</td>
<td>-1.8*</td>
</tr>
<tr>
<td>Pancreas</td>
<td>6.2</td>
<td>2.2</td>
<td>5.5</td>
<td>-1.1</td>
<td>7.2</td>
<td>2.0*</td>
</tr>
<tr>
<td>Liver &amp; IBD f</td>
<td>5.6</td>
<td>2.2</td>
<td>5.5</td>
<td>-1.1</td>
<td>7.2</td>
<td>2.0*</td>
</tr>
<tr>
<td>Stomach</td>
<td>5.5</td>
<td>-1.1</td>
<td>5.1</td>
<td>-0.4</td>
<td>6.5</td>
<td>0.6</td>
</tr>
<tr>
<td>Ovary</td>
<td>4.9</td>
<td>0.6</td>
<td>4.9</td>
<td>0.6</td>
<td>6.2</td>
<td>-0.6</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>4.4</td>
<td>2.1</td>
<td>4.1</td>
<td>-1.8</td>
<td>3.8</td>
<td>-3.0*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>3.2</td>
<td>-4.7*</td>
<td>3.8</td>
<td>0.4</td>
<td>3.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Leukemia</td>
<td>2.9</td>
<td>-0.5</td>
<td>2.9</td>
<td>-0.5</td>
<td>3.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>2.7</td>
<td>2.6*</td>
<td>2.6</td>
<td>0.3</td>
<td>2.9</td>
<td>0.6</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

- The APC is significantly different from zero (p<.05).
- Mortality data are analyzed from a public use file provided by the National Center for Health Statistics (NCHS).
- Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.
- History = HCC = Hepatitis C Virus.
### Table I-23

**AGE-ADJUSTED RATES AND TRENDS³ FOR THE TOP 15 CANCER SITES⁶ BY RACE/ETHNICITY**

#### Males

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>White</th>
<th>Rate</th>
<th>APC</th>
<th>Black</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Sites</strong></td>
<td>258.6</td>
<td>-1.65</td>
<td></td>
<td>360.5</td>
<td>-2.00</td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>80.8</td>
<td>-1.90</td>
<td></td>
<td>Lung and Bronchus</td>
<td>109.1</td>
<td>-2.50</td>
</tr>
<tr>
<td>Prostate</td>
<td>33.9</td>
<td>-3.60</td>
<td></td>
<td>Prostate</td>
<td>73.7</td>
<td>-2.50</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>26.3</td>
<td>-2.00</td>
<td></td>
<td>Colon and Rectum</td>
<td>34.8</td>
<td>-0.80</td>
</tr>
<tr>
<td>Pancreas</td>
<td>12.3</td>
<td>-0.30</td>
<td></td>
<td>Pancreas</td>
<td>16.4</td>
<td>-1.50</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>10.4</td>
<td>-0.70</td>
<td></td>
<td>Stomach</td>
<td>14.1</td>
<td>-3.00</td>
</tr>
<tr>
<td>Leukemia</td>
<td>10.4</td>
<td>-0.70</td>
<td></td>
<td>Esophagus</td>
<td>12.9</td>
<td>-4.40</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>7.7</td>
<td>-0.60</td>
<td></td>
<td>Leukemia</td>
<td>9.3</td>
<td>-1.10</td>
</tr>
<tr>
<td>Esophagus</td>
<td>7.6</td>
<td>-0.60</td>
<td></td>
<td>Liver &amp; IBD⁶</td>
<td>9.2</td>
<td>1.30</td>
</tr>
<tr>
<td>Stomach</td>
<td>7.1</td>
<td>-3.40</td>
<td></td>
<td>Myeloma</td>
<td>9.1</td>
<td>1.20</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>6.2</td>
<td>-0.10</td>
<td></td>
<td>Oral Cavity and Pharynx</td>
<td>8.2</td>
<td>-4.60</td>
</tr>
<tr>
<td>Brain and ONS⁷</td>
<td>5.7</td>
<td>-0.70</td>
<td></td>
<td>Non-Hodgkin Lymphoma</td>
<td>7.4</td>
<td>-0.60</td>
</tr>
<tr>
<td>Myeloma</td>
<td>4.8</td>
<td>-0.50</td>
<td></td>
<td>Kidney and Renal Pelvis</td>
<td>6.2</td>
<td>0.10</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>4.5</td>
<td>-2.70</td>
<td></td>
<td>Urinary Bladder</td>
<td>5.9</td>
<td>-2.10</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>3.9</td>
<td>-0.10</td>
<td></td>
<td>Larynx</td>
<td>5.7</td>
<td>-2.90</td>
</tr>
</tbody>
</table>

#### Asian/Pacific Islander

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Rate</th>
<th>APC</th>
<th></th>
<th>Rate</th>
<th>APC</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Sites</strong></td>
<td>155.7</td>
<td>-2.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>41.1</td>
<td>-1.90</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>16.4</td>
<td>-1.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; IBD⁶</td>
<td>15.9</td>
<td>-0.60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>14.1</td>
<td>-5.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>12.6</td>
<td>-3.90</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>8.4</td>
<td>-2.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>6.6</td>
<td>-2.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>5.4</td>
<td>-1.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>3.8</td>
<td>-2.80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>3.6</td>
<td>-3.70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>2.9</td>
<td>0.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>2.7</td>
<td>-0.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain and ONS⁷</td>
<td>2.4</td>
<td>3.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.2</td>
<td>-2.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.1</td>
<td>-4.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### American Indian/Alaska Native

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Rate</th>
<th>APC</th>
<th></th>
<th>Rate</th>
<th>APC</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Sites</strong></td>
<td>165.5</td>
<td>-1.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>50.0</td>
<td>-2.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>21.5</td>
<td>-4.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; IBD⁶</td>
<td>16.1</td>
<td>1.70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>7.6</td>
<td>1.60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>7.4</td>
<td>-1.70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>6.8</td>
<td>0.80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>6.3</td>
<td>1.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>5.1</td>
<td>3.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>3.6</td>
<td>-1.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>4.8</td>
<td>1.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>3.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain and ONS⁷</td>
<td>2.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.4</td>
<td>0.90</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>1.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Hispanic²

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Rate</th>
<th>APC</th>
<th></th>
<th>Rate</th>
<th>APC</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All Sites</strong></td>
<td>175.7</td>
<td>-0.90</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>40.4</td>
<td>-1.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>24.7</td>
<td>-2.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; IBD⁶</td>
<td>17.9</td>
<td>-0.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>10.2</td>
<td>1.60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td>10.0</td>
<td>-2.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>9.4</td>
<td>-0.80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>6.8</td>
<td>1.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>6.7</td>
<td>-1.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>5.5</td>
<td>0.70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophagus</td>
<td>4.5</td>
<td>-1.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>4.2</td>
<td>-0.70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloma</td>
<td>3.8</td>
<td>4.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain and ONS⁷</td>
<td>3.5</td>
<td>0.50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft Tissue including Heart</td>
<td>3.2</td>
<td>-0.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

The APC is the Annual Percent Change over the time interval.

Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.


Mortality data are analyzed from a public use file provided by the National Center for Health Statistics (NCHS).

Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

The APC is significantly different from zero (p<.05).

IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
### Table I-24

**AGE-ADJUSTED RATES AND TRENDS * for the Top 15 Cancer Sites**

**by Race/Ethnicity**

#### Females

<table>
<thead>
<tr>
<th>All Races</th>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>169.2</td>
<td>-0.7*</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>40.3</td>
<td>0.6*</td>
</tr>
<tr>
<td>Breast</td>
<td>28.5</td>
<td>-2.4*</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>18.3</td>
<td>-1.8*</td>
</tr>
<tr>
<td>Pancreas</td>
<td>9.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Ovary</td>
<td>9.0</td>
<td>-0.5*</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>6.8</td>
<td>-0.9</td>
</tr>
<tr>
<td>Leukemia</td>
<td>5.9</td>
<td>-0.6*</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>4.1</td>
<td>-0.1</td>
</tr>
<tr>
<td>Brain and ONS</td>
<td>3.8</td>
<td>-1.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>3.4</td>
<td>-2.6*</td>
</tr>
<tr>
<td>Myeloma</td>
<td>3.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>3.0</td>
<td>-3.1</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>2.9</td>
<td>1.2</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>2.8</td>
<td>-0.4</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>2.3</td>
<td>-0.4</td>
</tr>
</tbody>
</table>

#### White

<table>
<thead>
<tr>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>167.9</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>41.1</td>
</tr>
<tr>
<td>Breast</td>
<td>28.0</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>17.8</td>
</tr>
<tr>
<td>Ovary</td>
<td>9.3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>8.9</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>7.1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>6.0</td>
</tr>
<tr>
<td>Brain and ONS</td>
<td>4.1</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>3.9</td>
</tr>
<tr>
<td>Stomach</td>
<td>3.0</td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.9</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>2.9</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>2.7</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>2.3</td>
</tr>
</tbody>
</table>

#### Black

<table>
<thead>
<tr>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>199.2</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>39.3</td>
</tr>
<tr>
<td>Breast</td>
<td>36.2</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>24.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>12.9</td>
</tr>
<tr>
<td>Ovary</td>
<td>7.6</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>7.0</td>
</tr>
<tr>
<td>Stomach</td>
<td>6.7</td>
</tr>
<tr>
<td>Leukemia</td>
<td>6.5</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>6.2</td>
</tr>
<tr>
<td>Myeloma</td>
<td>5.5</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>4.5</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>3.7</td>
</tr>
<tr>
<td>Esophagus</td>
<td>3.5</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>3.0</td>
</tr>
</tbody>
</table>

#### Asian/Pacific Islander

<table>
<thead>
<tr>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>102.3</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>19.0</td>
</tr>
<tr>
<td>Breast</td>
<td>12.9</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>11.3</td>
</tr>
<tr>
<td>Stomach</td>
<td>7.5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>6.7</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>6.5</td>
</tr>
<tr>
<td>Ovary</td>
<td>4.8</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>4.1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.4</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>2.9</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>2.2</td>
</tr>
<tr>
<td>Brain and ONS</td>
<td>1.6</td>
</tr>
<tr>
<td>Myeloma</td>
<td>1.6</td>
</tr>
<tr>
<td>Oral Cavity and Pharynx</td>
<td>1.5</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>1.2</td>
</tr>
</tbody>
</table>

#### American Indian/Alaska Native

<table>
<thead>
<tr>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>115.2</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>26.4</td>
</tr>
<tr>
<td>Breast</td>
<td>14.4</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>12.1</td>
</tr>
<tr>
<td>Pancreas</td>
<td>6.1</td>
</tr>
<tr>
<td>Ovary</td>
<td>5.1</td>
</tr>
<tr>
<td>Stomach</td>
<td>4.2</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>4.1</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>3.8</td>
</tr>
<tr>
<td>Leukemia</td>
<td>3.4</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>3.2</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>2.7</td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.6</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>1.7</td>
</tr>
<tr>
<td>Brain and ONS</td>
<td>1.6</td>
</tr>
</tbody>
</table>

#### Hispanic

<table>
<thead>
<tr>
<th>Rate</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Sites</td>
<td>112.1</td>
</tr>
<tr>
<td>Breast</td>
<td>17.7</td>
</tr>
<tr>
<td>Lung and Bronchus</td>
<td>14.9</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>11.5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>7.6</td>
</tr>
<tr>
<td>Ovary</td>
<td>6.2</td>
</tr>
<tr>
<td>Stomach</td>
<td>5.5</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>5.3</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>4.8</td>
</tr>
<tr>
<td>Leukemia</td>
<td>4.3</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>3.8</td>
</tr>
<tr>
<td>Corpus and Uterus, NOS</td>
<td>3.2</td>
</tr>
<tr>
<td>Myeloma</td>
<td>2.7</td>
</tr>
<tr>
<td>Brain and ONS</td>
<td>2.5</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>2.4</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1.8</td>
</tr>
</tbody>
</table>

---

The APC is the Annual Percent Change over the time interval.

* Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.


* Mortality data are analyzed from a public use file provided by the National Center for Health Statistics (NCHS).

Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

* The APC is significantly different from zero (p < 0.05).

IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
Surveillance, Epidemiology, and End Results Program, 2005
National Cancer Institute
U.S.A

- Seattle/Puget Sound
- San Francisco/San Jose/Monterey
- Los Angeles
- New Mexico
- Utah
- Iowa
- Detroit
- Connecticut
- New Jersey
- Rural Georgia
- Alaska
- Hawaii

Expansion Registries

SEER 13

Data not used in Cancer Statistics Review calculations.
* Greater California is the state of California excluding San Francisco/Oakland, San Jose/Monterey and Los Angeles areas.
http://seer.cancer.gov
Leading Causes of Death in US
Percent of All Causes of Death
1975 vs 2002

1975
Cerebrovascular 10.3%
Chronic Lung Disease 2.3%
Heart Disease 37.8%
Accidents 5.4%
Other Causes 22.0%
Pneumonia & Influ. 2.9%
Cancer 19.2%

2002
Cerebrovascular 6.7%
Chronic Lung Disease 5.1%
Heart Disease 28.5%
Accidents 4.4%
Other Causes 29.8%
Pneumonia & Influ. 2.7%
Cancer 22.8%

Source: NCHS public use data file for the total US.
US Death Rates
1975-2002

Ages Less Than 65

Heart Disease

Neoplasms

26% of deaths in 1975

22% of deaths in 1975

26% of deaths in 2002

19% of deaths in 2002

Ages 65 and Over

Heart Disease

Neoplasms

44% of deaths in 1975

18% of deaths in 1975

32% of deaths in 2002

22% of deaths in 2002

Rate per 100,000

Year of Death

1975 1984 1993 2002

1975 1984 1993 2002

Source: NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Trends in SEER Incidence Rates

Thyroid: 4.3*
Liver & IBD: 3.3*
Melanoma of the Skin: 2.4*
Kidney & Renal Pelvis: 1.5*
Testis: 1.1*
Breast (Female): 0.4
Non-Hodgkin Lymphoma: 0.1
Esophagus: 0.0
Urinary Bladder: -0.2
Lung & Bronchus (Female): -0.2
Corpus & Uterus, NOS: -0.2
Pancreas: -0.3
Hodgkin Lymphoma: -0.3
All Except Lung: -0.5*
Myeloma: -0.5
All Cancer Sites: -0.6*
Brain & ONS: -0.6*
Colon & Rectum: -0.8*
Leukemia: -0.9*
Ovary: -0.9*
Oral Cavity & Pharynx: -1.5*
Stomach: -1.5*
Prostate: -2.0*
Lung & Bronchus (Male): -2.2*
Cervix Uteri: -2.8*
Larynx: -3.0*

Trends in US Cancer Death Rates

Liver & IBD: -0.6*
Esophagus: 0.6*
Thyroid: 0.6*
Lung & Bronchus (Female): -0.1
Pancreas: -0.1
Kidney & Renal Pelvis: -0.1
Corpus & Uterus, NOS: -0.3
Melanoma of the Skin: -0.3
Urinary Bladder: -0.3*
Myeloma: -0.4*
Ovary: -0.5*
Leukemia: -0.6*
Testis: -0.6
Non-Hodgkin Lymphoma: -0.8
Brain & ONS: -0.9*
All Cancer Sites: -1.0*
All Except Lung: -1.1*
Colon & Rectum: -1.8*
Lung & Bronchus (Male): -1.9*
Larynx: -2.1*
Breast (Female): -2.4*
Larynx: -2.5*
Oral Cavity & Pharynx: -3.0*
Stomach: -3.1*
Cervix Uteri: -3.2*
Hodgkin Lymphoma: -3.6*
Prostate: -3.6*

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia) and NCHS public use data file for the total US.
Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero (p<.05).
Trends in SEER Incidence Rates by Primary Cancer Site 1992-2002

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero (p<.05).
Figure I-6


Ages Less Than 65

Liver & IBD
Corpus & Uterus, NOS
Thyroid
Pancreas
Urinary Bladder
Testis
Esophagus
Kidney & Renal Pelvis
Ovary
Brain & ONS
Colon & Rectum
All Except Lung
Myeloma
Melanoma of the Skin
Lung & Bronchus (Female)
All Cancer Sites
Leukemia
Cervix Uteri
Stomach
Breast (Female)
Oral Cavity & Pharynx
Larynx
Non-Hodgkin Lymphoma
Lung & Bronchus (Male)
Prostate
Hodgkin Lymphoma

APC, 1992-2002

-8 -6 -4 -2 0 2 4 6 8

-4.4* -4.2* -3.7* -3.1* -2.9* -2.2* -2.0* -1.3*

1.7* 1.5* 1.3* 0.9* 0.6* 0.4* 0.2* 0.2*

Source: NCHS public use data file for the total US.
Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero (p<.05).
Trends in SEER Incidence Rates by Primary Cancer Site 1992-2002

All Races, Males

Thyroid
Liver & IBD
Melanoma of the Skin
Kidney & Renal Pelvis
Testis
Esophagus
Hodgkin Lymphoma
Urinary Bladder
Pancreas
Non-Hodgkin Lymphoma
Myeloma
Brain & ONS
Leukemia
All Except Lung
Colon & Rectum
All Cancer Sites
Oral Cavity & Pharynx
Prostate
Stomach
Lung & Bronchus
Larynx

APC, 1992-2002

-3.3*
-2.2*
-1.8*
-2.0*
-2.1*
-1.3*
-1.2*
-1.2*
-1.8*
-1.5*
-0.4*
-0.2
0.3
1.1*
1.4*
2.5*
3.0*
3.1*

All Races, Females

Thyroid
Liver & IBD
Melanoma of the Skin
Kidney & Renal Pelvis
Non-Hodgkin Lymphoma
Breast
All Cancer Sites
All Except Lung
Lung & Bronchus
Corpus & Uterus, NOS
Pancreas
Urinary Bladder
Brain & ONS
Hodgkin Lymphoma
Colon & Rectum
Stomach
Myeloma
Leukemia
Ovary
Esophagus
Oral Cavity & Pharynx
Larynx
Cervix Uteri

APC, 1992-2002

-2.8*
-2.4*
-1.1*
-1.0*
-0.9*
-0.8*
-0.8*
-0.6*
-0.6*
-0.4*
-0.4*
-0.3
-0.2
0.1
0.4
0.8*
1.4*
2.3*
4.8*

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero (p<.05).

Source: NCHS public use data file for the total US. Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
The APC is the Annual Percent Change over the time interval.
* The APC is significantly different from zero (p<.05).
SEER Incidence\(^*\) and US Death Rates\(^\#\) 1998-2002
5-Year Relative Survival Rates,\(^\wedge\) 1995-2001
All Cancer Combined, by Race and Sex

---

**Males**

<table>
<thead>
<tr>
<th>Rate per 100,000</th>
<th>SEER Incidence</th>
<th>US Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Incidence rates are from the SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia) and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Survival, 1995-2001</th>
<th>Percent (%)</th>
<th>Black</th>
<th>White</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>70</td>
<td>60</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>60</td>
<td>50</td>
</tr>
<tr>
<td>20</td>
<td>20</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>30</td>
<td>30</td>
<td>40</td>
<td>30</td>
</tr>
<tr>
<td>40</td>
<td>40</td>
<td>30</td>
<td>20</td>
</tr>
<tr>
<td>50</td>
<td>50</td>
<td>20</td>
<td>10</td>
</tr>
</tbody>
</table>

*Death rates are from the NCHS public use data file for the total US and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).*

---

**Females**

<table>
<thead>
<tr>
<th>Rate per 100,000</th>
<th>SEER Incidence</th>
<th>US Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Survival rates are from the SEER 9 areas. Relative survival rates are expressed as percents.</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Survival, 1995-2001</th>
<th>Percent (%)</th>
<th>Black</th>
<th>White</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>70</td>
<td>60</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>60</td>
<td>50</td>
</tr>
<tr>
<td>20</td>
<td>20</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>30</td>
<td>30</td>
<td>40</td>
<td>30</td>
</tr>
<tr>
<td>40</td>
<td>40</td>
<td>30</td>
<td>20</td>
</tr>
<tr>
<td>50</td>
<td>50</td>
<td>20</td>
<td>10</td>
</tr>
</tbody>
</table>
Figure I-10

by Primary Cancer Site
All Ages, by Race

Source: NCHS public use data file for the total US.
The APC is the Annual Percent Change over the time interval.
Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
Figure I-11

5-Year Relative Survival Rates
SEER Program, 1995-2001
Both Sexes, by Race

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>White Patients</th>
<th>Black Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>100</td>
<td>97</td>
</tr>
<tr>
<td>Thyroid</td>
<td>97</td>
<td>95</td>
</tr>
<tr>
<td>Testis</td>
<td>96</td>
<td>88</td>
</tr>
<tr>
<td>Melanoma of the Skin</td>
<td>92</td>
<td>78</td>
</tr>
<tr>
<td>Breast (Female)</td>
<td>90</td>
<td>76</td>
</tr>
<tr>
<td>Corpus &amp; Uterus, NOS</td>
<td>86</td>
<td>62</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>86</td>
<td>80</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>83</td>
<td>64</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>75</td>
<td>66</td>
</tr>
<tr>
<td>Larynx</td>
<td>68</td>
<td>51</td>
</tr>
<tr>
<td>Rectum</td>
<td>65</td>
<td>56</td>
</tr>
<tr>
<td>Colon</td>
<td>65</td>
<td>55</td>
</tr>
<tr>
<td>Kidney &amp; Renal Pelvis</td>
<td>62</td>
<td>64</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx</td>
<td>61</td>
<td>40</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>49</td>
<td>52</td>
</tr>
<tr>
<td>Leukemia</td>
<td>49</td>
<td>38</td>
</tr>
<tr>
<td>Kaposi Sarcoma</td>
<td>44</td>
<td>34</td>
</tr>
<tr>
<td>Ovary</td>
<td>33</td>
<td>38</td>
</tr>
<tr>
<td>Brain &amp; ONS</td>
<td>32</td>
<td>38</td>
</tr>
<tr>
<td>Myeloma</td>
<td>21</td>
<td>33</td>
</tr>
<tr>
<td>Stomach</td>
<td>16</td>
<td>23</td>
</tr>
<tr>
<td>Esophagus</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>Lung &amp; Bronchus</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>9</td>
<td>15</td>
</tr>
<tr>
<td>Liver &amp; IBD</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Pancreas</td>
<td></td>
<td>4</td>
</tr>
</tbody>
</table>

Source: SEER 9 areas.
Figure I-12

By Cancer Site and Race

Incidences

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>White</th>
<th>Black</th>
<th>Asian/Pacific Islander</th>
<th>Am. Indian/Alaska Nat.</th>
<th>Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>61.8</td>
<td>79.0</td>
<td>41.8</td>
<td>31.8</td>
<td>32.0</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>52.5</td>
<td>62.4</td>
<td>46.8</td>
<td>34.2</td>
<td>39.1</td>
</tr>
<tr>
<td>Breast (Female)</td>
<td>141.1</td>
<td>119.4</td>
<td>96.6</td>
<td>54.8</td>
<td>89.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>169.0</td>
<td>272.0</td>
<td>101.4</td>
<td>50.3</td>
<td>141.9</td>
</tr>
</tbody>
</table>

Mortality

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>White</th>
<th>Black</th>
<th>Asian/Pacific Islander</th>
<th>Am. Indian/Alaska Nat.</th>
<th>Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung and Bronchus</td>
<td>55.8</td>
<td>64.1</td>
<td>27.7</td>
<td>35.4</td>
<td>24.8</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>20.0</td>
<td>27.9</td>
<td>12.8</td>
<td>13.7</td>
<td>14.2</td>
</tr>
<tr>
<td>Breast (Female)</td>
<td>25.9</td>
<td>34.7</td>
<td>12.7</td>
<td>13.8</td>
<td>16.7</td>
</tr>
<tr>
<td>Prostate</td>
<td>27.7</td>
<td>68.1</td>
<td>12.1</td>
<td>18.3</td>
<td>23.0</td>
</tr>
</tbody>
</table>

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia) and NCHS public use data file for the total US.
Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics excludes cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia. Mortality data for Hispanics excludes cases from Connecticut, Maine, Maryland, Minnesota, Oklahoma, New Hampshire, New York, North Dakota, and Vermont.
Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Incidence data for Hispanics excludes cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.

# API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^ ^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Incidence data for Hispanics excludes cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.

# API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
Males by Race/Ethnicity

Prostate
Rate per 100,000

Lung and Bronchus
Rate per 100,000

Colon and Rectum
Rate per 100,000

Source: NCHS public use data file for the total US. Mortality data for Hispanics excludes cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

# API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
Females by Race/Ethnicity

Breast

Lung and Bronchus

Colon and Rectum

Source: NCHS public use data file for the total US. Mortality data for Hispanics excludes cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.
Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

# API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^ ^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
Incidence Percent Change, 1992-2002
Numbers (burden) vs Rates (risk)
All Ages

US Incidence estimates based on SEER age-specific rates applied to US population.
Mortality Percent Change, 1992-2002
Numbers (burden) vs Rates (risk)
All Ages

US Mortality estimates based on US age-specific rates applied to US population.
Person-Years of Life Lost Due to Cancer, All Races Both Sexes, 2002

Average Years of Life Lost Per Person Dying of Cancer All Races, Both Sexes, 2002

Source: NCHS public use data file for the total US and 2002 Life Tables.
Person-Years of Life Lost
Due to Major Causes of Death in US
All Races, Both Sexes, 2002

<table>
<thead>
<tr>
<th>Cause</th>
<th>Years in Millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant Neoplasms</td>
<td>8.6</td>
</tr>
<tr>
<td>Heart Disease</td>
<td>7.9</td>
</tr>
<tr>
<td>All Other Causes</td>
<td>7.3</td>
</tr>
<tr>
<td>Accidents</td>
<td>3.4</td>
</tr>
<tr>
<td>Cerebrovascular</td>
<td>1.7</td>
</tr>
<tr>
<td>Chronic Lung Disease</td>
<td>1.4</td>
</tr>
<tr>
<td>Suicide &amp; Self-Inflicted Injury</td>
<td>1.1</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>1.0</td>
</tr>
<tr>
<td>Homicide</td>
<td>0.8</td>
</tr>
<tr>
<td>Pneumonia &amp; Influenza</td>
<td>0.6</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>0.6</td>
</tr>
<tr>
<td>HIV *</td>
<td>0.5</td>
</tr>
<tr>
<td>Nephritis &amp; Nephrosis</td>
<td>0.5</td>
</tr>
<tr>
<td>Septicemia</td>
<td>0.5</td>
</tr>
<tr>
<td>Alzheimers Disease</td>
<td>0.4</td>
</tr>
<tr>
<td>Aortic Aneurysm &amp; Dissection</td>
<td>0.2</td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td>0.1</td>
</tr>
</tbody>
</table>

Average Years of Life Lost Per Person
Due to Major Causes of Death in US
All Races, Both Sexes, 2002

<table>
<thead>
<tr>
<th>Cause</th>
<th>Years in Millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homicide</td>
<td>45.3</td>
</tr>
<tr>
<td>HIV *</td>
<td>34.8</td>
</tr>
<tr>
<td>Suicide &amp; Self-Inflicted Injury</td>
<td>33.8</td>
</tr>
<tr>
<td>Accidents</td>
<td>32.1</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>22.3</td>
</tr>
<tr>
<td>All Other Causes</td>
<td>18.2</td>
</tr>
<tr>
<td>Malignant Neoplasms</td>
<td>15.4</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>14.2</td>
</tr>
<tr>
<td>Septicemia</td>
<td>13.7</td>
</tr>
<tr>
<td>Aortic Aneurysm &amp; Dissection</td>
<td>12.4</td>
</tr>
<tr>
<td>Nephritis &amp; Nephrosis</td>
<td>11.8</td>
</tr>
<tr>
<td>Chronic Lung Disease</td>
<td>11.6</td>
</tr>
<tr>
<td>Heart Disease</td>
<td>11.4</td>
</tr>
<tr>
<td>Cerebrovascular</td>
<td>10.3</td>
</tr>
<tr>
<td>Pneumonia &amp; Influenza</td>
<td>9.7</td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td>7.8</td>
</tr>
<tr>
<td>Alzheimers Disease</td>
<td>6.9</td>
</tr>
</tbody>
</table>

Source: NCHS public use data file for the total US and 2002 Life Tables.
* Human Immunodeficiency Virus
Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero (p < 0.05).
SEER Incidence and Delay Adjusted Incidence Rates

Both Sexes

Lung and Bronchus

Colon and Rectum

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero (p < 0.05).
SEER Incidence and Delay Adjusted Incidence Rates* Males

Prostate
Rate per 100,000
Year of Diagnosis
1975 1984 1993 2002
APC = 1.7*

Lung and Bronchus
Rate per 100,000
Year of Diagnosis
1975 1984 1993 2002
APC = -1.8*

Colon and Rectum
Rate per 100,000
Year of Diagnosis
1975 1984 1993 2002
APC = -2.5*

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero (p < 0.05).
SEER Incidence and Delay Adjusted Incidence Rates for Females

Breast
- APC = 0.4*
- APC = 0.3*

Lung and Bronchus
- APC = -0.5
- APC = -1.1

Colon and Rectum
- APC = -1.5*
- APC = -1.9*

Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero (p < 0.05).
All Races, Both Sexes

Overall Decreasing Regression Coefficient : -2.75

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Percents may not add to 100 due to rounding.
All Races, Males

Overall Decreasing Regression Coefficient : -7.90

Change in Incidence Rate (Cases/100,000/Year)

-10 -8 -6 -4 -2 0 2

Overall Net Trend
Overall Decreasing Trend
Prostate
Lung & Bronchus
All Other Sites
Colon & Rectum
Oral Cavity & Pharynx
Stomach
Leukemia
Non-Hodgkin Lymphoma
Urinary Bladder
Brain & ONS
Pancreas
Overall Increasing Trend
Melanoma of the Skin

% of decreasing
45.0%
21.9%
11.7%
9.0%
3.6%
3.3%
2.1%
1.2%
1.0%
0.6%
0.5%
100.0%

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Percents may not add to 100 due to rounding.
All Races, Females

Overall Increasing Regression Coefficient: 0.28

Change in Incidence Rate (Cases/100,000/Year)

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
Percents may not add to 100 due to rounding.
All Races, Both Sexes

Overall Decreasing Regression Coefficient : -2.13

Source: NCHS public-use file for the total US.
Percents may not add to 100 due to rounding.
All Races, Males

Overall Decreasing Regression Coefficient : -3.87

Source: NCHS public-use file for the total US.
Percents may not add to 100 due to rounding.
All Races, Females

Overall Decreasing Regression Coefficient: -1.26

Overall Net Trend
Overall Decreasing Trend
Breast
Colon & Rectum
Cervix Uteri
Stomach
Non-Hodgkin Lymphoma
Ovary
Oral Cavity & Pharynx
All Other Sites
Brain & ONS
Leukemia
Melanoma of the Skin
Urinary Bladder
Pancreas
Corpus & Uterus, NOS
Overall Increasing Trend
Lung & Bronchus

Change in Death Rate (Deaths/100,000/Year)

% of decreasing
45.6%
22.1%
6.5%
6.1%
3.9%
3.0%
2.8%
2.8%
2.7%
2.3%
0.8%
0.6%
0.5%
0.4%
100.0%

Source: NCHS public-use file for the total US.
Percents may not add to 100 due to rounding.